var title_f35_53_36688="Disseminated granuloma annulare on trunk";
var content_f35_53_36688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated granuloma annulare",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 64 year-old woman with disseminated granuloma annulare displays solitary papules and incomplete annular lesions composed of discrete papules at the periphery of the rings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36688=[""].join("\n");
var outline_f35_53_36688=null;
var title_f35_53_36689="Perforation of the cervical esophagus";
var content_f35_53_36689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforation of the cervical esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts a flexible esophagoscope perforating Killian's triangle, which is the posterior space between the oblique inferior constrictor and the cricopharyngeus muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36689=[""].join("\n");
var outline_f35_53_36689=null;
var title_f35_53_36690="Patient information: Aortic stenosis (The Basics)";
var content_f35_53_36690=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16658\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/7/14452\">",
"         Aortic stenosis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/35/34354\">",
"          Transthoracic echocardiogram (echo)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7154\">",
"           Person having an ECG",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/23/11635\">",
"         Patient information: Prosthetic valves (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/5/36946\">",
"         Patient information: Syncope (fainting) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Aortic stenosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/aortic-stenosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26013526\">",
"      <span class=\"h1\">",
"       What is aortic stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Aortic stenosis is a condition in which one of the valves in the heart, called the aortic valve, doesn&rsquo;t open fully (",
"      <a class=\"graphic graphic_figure graphicRef74714 \" href=\"mobipreview.htm?14/7/14452\">",
"       figure 1",
"      </a>",
"      ). The heart valves keep blood flowing in only 1 direction. When the heart valves work normally, they open all the way to let blood flow through them.",
"     </p>",
"     <p>",
"      Blood flows from a chamber of the heart called the left ventricle, through the aortic valve, into a large blood vessel called the aorta (",
"      <a class=\"graphic graphic_figure graphicRef74714 \" href=\"mobipreview.htm?14/7/14452\">",
"       figure 1",
"      </a>",
"      ). The aorta carries blood to the rest of the body.",
"     </p>",
"     <p>",
"      In aortic stenosis, the aortic valve gets stuck and does not open fully. This makes the valve opening narrow. When this happens:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not as much blood can flow out of the heart to the rest of the body.",
"       </li>",
"       <li>",
"        The heart has to work much harder than usual to pump blood to the rest of the body. Over time, this can cause heart problems.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Aortic stenosis usually happens in adults. But some people are born with aortic stenosis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26013541\">",
"      <span class=\"h1\">",
"       What are the symptoms of aortic stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early on, most people have no symptoms. They usually find out they have aortic stenosis after their doctor or nurse hears a heart murmur on a routine exam. A heart murmur is an extra sound in the heartbeat that doctors or nurses hear when they listen to the heart with a stethoscope.",
"     </p>",
"     <p>",
"      When people do have symptoms, they can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Shortness of breath",
"       </li>",
"       <li>",
"        Dizziness or fainting",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms usually happen with physical activity. Let your doctor know if you have any of these symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26013556\">",
"      <span class=\"h1\">",
"       Is there a test for aortic stenosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for aortic stenosis and see how severe it is, your doctor might order an echocardiogram (or &ldquo;echo&rdquo;). This test uses sound waves to create a picture of your heart as it beats. It shows the size of the heart chambers, how well the heart is pumping, and how well the heart valves are working (",
"      <a class=\"graphic graphic_figure graphicRef77971 \" href=\"mobipreview.htm?33/35/34354\">",
"       figure 2",
"      </a>",
"      ). If you have aortic stenosis, your doctor might repeat this test over time to see if your condition changes.",
"     </p>",
"     <p>",
"      To get more information about your heart, your doctor might order a test called cardiac catheterization (or cardiac &ldquo;cath&rdquo;). During this procedure, a doctor puts a thin tube into a blood vessel in your leg and moves it up to your heart. When the tube is in your heart, he or she will take measurements in different parts of your heart. He or she might also inject a dye into the tube that shows up on an X-ray. This dye can show if any of the arteries in your heart are narrowed or blocked.",
"     </p>",
"     <p>",
"      All people with aortic stenosis will have a test called an electrocardiogram (ECG or EKG). This test measures the electrical activity in your heart (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"mobipreview.htm?6/63/7154\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Some people with aortic stenosis will also have a chest X-ray. A chest X-ray can show the size and shape of your heart. It can also show changes in your lungs from aortic stenosis or other diseases.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26013571\">",
"      <span class=\"h1\">",
"       How is aortic stenosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms and how severe your aortic stenosis is. If your aortic stenosis is mild or you have little or no symptoms, you might not need any treatment. But your doctor will follow you to see if your aortic stenosis gets worse or you start to have symptoms.",
"     </p>",
"     <p>",
"      If your aortic stenosis is severe or you have a lot of symptoms, you will likely need treatment. Treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery to replace your aortic valve &ndash; During surgery, the doctor will remove your narrowed valve and replace it with a valve that opens normally. This new valve can be made from metal or from valve tissue from a pig, cow, or horse. In some cases, a new valve comes from another person. Your doctor will talk with you about the benefits and downsides of each option.",
"       </li>",
"       <li>",
"        Medicines &ndash; There are no medicines to treat aortic stenosis. But if you have other heart conditions besides aortic stenosis, your doctor might prescribe medicines to treat those conditions. He or she will also make sure your blood pressure and cholesterol level are under control.",
"       </li>",
"       <li>",
"        A procedure to open the aortic valve &ndash; For this procedure, a doctor inflates a balloon in the narrowed aortic valve to try to open it. This procedure is used in children and young adults, because it is helpful in these people. This procedure is rarely done in older adults, because it is not as helpful for them.",
"       </li>",
"       <li>",
"        Getting a new aortic valve without surgery &ndash; This is a new type of procedure that doctors in Europe can do to treat people who can&rsquo;t have surgery. It is still being studied in the United States.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26013586\">",
"      <span class=\"h1\">",
"       Can I play sports?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your aortic stenosis is mild or you have little or no symptoms, you can probably play sports. But if your aortic stenosis or symptoms are more serious, your doctor might recommend that you limit your physical activity. That&rsquo;s because when you are very active, your heart has to work harder than usual. If you have aortic stenosis, this can overwork your heart.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26013601\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse. Depending on your aortic stenosis and symptoms, he or she might recommend treating your aortic stenosis before you get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26013616\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/5/36946?source=see_link\">",
"       Patient information: Syncope (fainting) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/23/11635?source=see_link\">",
"       Patient information: Prosthetic valves (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/53/36690?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16658 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-18180375D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36690=[""].join("\n");
var outline_f35_53_36690=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26013526\">",
"      What is aortic stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26013541\">",
"      What are the symptoms of aortic stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26013556\">",
"      Is there a test for aortic stenosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26013571\">",
"      How is aortic stenosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26013586\">",
"      Can I play sports?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26013601\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26013616\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16658\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/7/14452\">",
"      Aortic stenosis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/35/34354\">",
"       Transthoracic echocardiogram (echo)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/63/7154\">",
"        Person having an ECG",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/23/11635?source=related_link\">",
"      Patient information: Prosthetic valves (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_53_36691="Micrograph schwannoma";
var content_f35_53_36691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micrograph schwannoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 268px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Photomicrograph of an intracranial schwannoma removed from the vestibular nerve. The tumor cell nuclei are spindle-shaped. At the top and bottom of the figure are areas of compact tissue (Antoni A pattern), while the middle of the figure consists of loose-textured tissue (Antoni B pattern). H&amp;E stain, 100x. B) Photomicrograph of a spinal schwannoma removed from the L2-3 nerve root. Palisading of nuclear and cytoplasmic processes of the tumor cells is shown in the center of the figure. This is a Verocay body. H&amp;E stain, 600x.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John E Donahue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36691=[""].join("\n");
var outline_f35_53_36691=null;
var title_f35_53_36692="Melasma PI";
var content_f35_53_36692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melasma on the cheek",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Melasma is a skin condition that causes brown patches on the face. This picture shows melasma on a woman's cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36692=[""].join("\n");
var outline_f35_53_36692=null;
var title_f35_53_36693="Sitagliptin and simvastatin: Patient drug information";
var content_f35_53_36693=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sitagliptin and simvastatin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/17/280?source=see_link\">",
"     see \"Sitagliptin and simvastatin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13458345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Juvisync&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13319482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13319484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to slow the progress of heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13319483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3547542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sitagliptin, simvastatin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have active liver disease or a rise in liver enzymes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13319488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13319489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13319491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13319486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the evening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4156299",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not split or break tablet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13319487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13319492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13319493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17091 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36693=[""].join("\n");
var outline_f35_53_36693=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13458345\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319482\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319484\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319483\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319488\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319489\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319491\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319486\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319487\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319492\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319493\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/17/280?source=related_link\">",
"      Sitagliptin and simvastatin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_53_36694="Palliative care: End-stage renal disease";
var content_f35_53_36694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Palliative care: End-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36694/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36694/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36694/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36694/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36694/contributors\">",
"     R Sean Morrison, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36694/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36694/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/53/36694/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasingly elderly end-stage renal disease (ESRD) population, particularly in the United States, requires nephrologists to focus upon issues relating to palliative care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The American Society of Nephrology (ASN) and Renal Physicians Association (RPA), for example, have sponsored evidence-based guidelines relating to withholding and withdrawing from dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/8\">",
"     8",
"    </a>",
"    ] and a United Kingdom Expert Consensus Group published guidelines for symptom management in adults dying with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since nearly 20 percent of dialysis patients stop dialysis prior to death, it is likely that all nephrologists will be involved in end-of-life care. As a group, however, physicians are poorly trained in palliative care and often feel uncomfortable with the care of dying patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In one survey of American and Canadian physicians, for example, only approximately 40 percent of 360 nephrologists stated that they were very well prepared to make end-of-life decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Providing palliative care to patients with chronic kidney disease begins at the time of diagnosis and continues throughout the patient's life. With progression of kidney disease, palliative care assumes increasing importance with time and is integral to \"good deaths.\" Dialysis unit staff should be involved in such care and also must recognize their responsibilities in the areas of advance care planning, pain and symptom management, and bereavement support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/1,6,8,12-15\">",
"     1,6,8,12-15",
"    </a>",
"    ]. A national survey of palliative care in the United Kingdom again demonstrated opportunities to improve this aspect of ESRD care and prompted the authors to suggest guidelines for renal palliative care initiatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss aspects of care that typically require attention in the patient who withdraws from dialysis or chooses not to initiate dialysis. Principles of palliative care will be addressed as well as guidelines for the use of analgesia in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF PALLIATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative care refers to the comprehensive management of the physical, psychological, social, spiritual, and existential needs of patients and families in the setting of serious illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/17\">",
"     17",
"    </a>",
"    ]. The goal of palliative care is to achieve the best possible quality of life by relieving suffering, controlling symptoms, and restoring functional capacity, while maintaining sensitivity to personal, cultural, and spiritual beliefs and practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/17\">",
"     17",
"    </a>",
"    ]. Throughout the course of a serious illness, palliative care assumes an increasing priority over disease-directed care and eventually focuses upon the dying process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Integral to the precepts of palliative care is an interdisciplinary approach focusing upon physical comfort (managing pain and other symptoms) and psychological, spiritual, and social support for the patient and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    family and community. With chronic kidney disease patients, the dialysis and transplant community, as well as the patient's identified family, will be involved in the giving and receiving of supportive care.",
"   </p>",
"   <p>",
"    Hospice referral, which is one aspect of palliative care, is appropriate for those expected to live less than six months if the disease follows its usual course, and for those who are willing to relinquish curative treatments. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"     \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no uniform policy about continuing dialysis for hospice patients. The specific hospice program's policy about continuing dialysis while a patient is receiving hospice care will need to be addressed on an individual basis. Similarly, Medicare reimbursement for hospice and dialysis requires clarification on a case-by-case basis for patients on dialysis who are referred for hospice care. Patients who withdraw from dialysis should be eligible for hospice in nearly all cases; yet, even in this group, hospice is under-utilized. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Symptom control after dialysis discontinuation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Important aspects of palliative care in the chronic kidney disease patient include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment of quality of life",
"     </li>",
"     <li>",
"      Advance directives",
"     </li>",
"     <li>",
"      Symptom control",
"     </li>",
"     <li>",
"      Morbidity and mortality review for quality of death",
"     </li>",
"     <li>",
"      Bereavement care for family and community",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Quality of life assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various tools have been used by individual nephrologists and dialysis programs to assess quality of life of patients. However, there is as yet no mandated use of such tools in dialysis units, and the most appropriate tool and its use in patient care have not yet been clarified. Depression, sexual dysfunction, reduced functional status, and low rates of employment are all relatively common among patients with chronic kidney disease.",
"   </p>",
"   <p>",
"    Quality of life assessment should begin with the diagnosis of kidney disease and continue until death. Periodic assessment of a patient's quality of life should therefore become as routine as are the current measurements of serum hemoglobin levels and dialysis adequacy. In addition, symptom assessment and treatment in ESRD patients are not routine but integral to quality of life assessment. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Symptom control after dialysis discontinuation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Advance directives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Living wills and health care proxies are referred to as advance directives, which are underutilized by patients with chronic kidney disease. Increased use of advance directives may occur if advance care planning is centered within the patient-family relationship, rather than within the patient-physician relationship, and if dialysis unit staff becomes more comfortable discussing these issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Although patients and families rarely discuss stopping dialysis as part of advance care planning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/21\">",
"     21",
"    </a>",
"    ], efforts to improve the advance care planning process may result in more attention being paid to this topic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Because advance directives are completed by a competent patient and not the physician, do not resuscitate (DNR) orders and physician orders for life-sustaining treatment (POLST) are not advance directives but are actual physician orders. Efforts to ensure that patient wishes for end-of-life care are followed led to the development of POLST which are appropriate in states and areas in which they are legal documents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/24\">",
"     24",
"    </a>",
"    ] Both POLST, where available, and DNR orders, are important documents for dialysis patients to consider as part of the advance care planning process.",
"   </p>",
"   <p>",
"    The contemporary view of advance directives emphasizes their use as a means of preparing for death, achieving control, relieving burdens on loved ones, and strengthening interpersonal relationships [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Time is thus provided for writing wills, discussing funeral arrangements, and attending to the psychosocial and spiritual concerns of the patient and family. The interdisciplinary approach to these issues in dialysis patients will involve nurses, social workers, physicians, religious counselors, and in some cases, peers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/19,25,26\">",
"     19,25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16165?source=see_link\">",
"     \"Ethical issues in the care of the patient with end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dialysis patients report relying on dialysis unit staff to address their palliative care needs (not only advance care planning but also pain and symptom management and psychological and spiritual support). However, less than 10 percent of patients report discussing end-of-life issues with their nephrologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/13\">",
"     13",
"    </a>",
"    ]. New approaches to advance care planning, especially in minority populations, may prove effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptom control after dialysis discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mean survival from the last dialysis treatment to death in a patient who stops dialysis is six to eight days, with a range of 2 to 100 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/2,28,29\">",
"     2,28,29",
"    </a>",
"    ]. Longer survival should be expected in patients with significant residual renal function.",
"   </p>",
"   <p>",
"    Most patients who withdraw from dialysis die in the hospital; they are rarely referred for hospice care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/30\">",
"     30",
"    </a>",
"    ]. As examples, ESRD patients composed only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      71 of 14,253",
"      <span class=\"nowrap\">",
"       patient/families",
"      </span>",
"      served by hospice in North Carolina in 1996",
"     </li>",
"     <li>",
"      29 of 4728 South Carolina",
"      <span class=\"nowrap\">",
"       patients/families",
"      </span>",
"      served by hospice in 1995",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of hospice claims from the USRDS Data system for the 115,239 dialysis patients who died between January 1, 2001 and December 31, 2002 showed that 22 percent of patients withdrew from dialysis, of whom 42 percent used hospice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/31\">",
"     31",
"    </a>",
"    ]. The median per patient cost of care in the last week of life was significantly lower in the group who withdrew and used hospice. This was primarily because only 23 percent of that group died in the hospital compared with 69 percent of the group who withdrew and did not use hospice. Factors associated with hospice use included patient age, race, reason for withdrawal, ability to walk or transfer at dialysis initiation, and state of residence. The authors concluded that hospice is underutilized among dialysis patients who withdraw from dialysis and that increased hospice use in this population may enable more patients to die at home with significant cost savings.",
"   </p>",
"   <p>",
"    Uremic deaths are generally described as painless and characterized by increasing somnolence. However, in one prospective study of deaths in patients withdrawing from dialysis, 42 percent of 79 patients were reported to be in pain by their",
"    <span class=\"nowrap\">",
"     families/loved",
"    </span>",
"    ones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/2\">",
"     2",
"    </a>",
"    ]. A survey by the same group of investigators of families of patients who had died found that 75 percent of patients were in pain during the last week of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/32\">",
"     32",
"    </a>",
"    ]. Underlying comorbid conditions such as peripheral vascular disease, coronary artery disease, and neuropathy were felt to be causes of the perceived pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reported symptoms include weakness, fatigue, agitation, depression, myoclonus or muscle twitching, dyspnea or agonal breathing, fever, diarrhea and dysphagia, and nausea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. General supportive care should be emphasized with interventions to ensure patient comfort such as lip balm, mouth swabs, positioning, back rubs, fans, and the elimination of blood draws and dietary restrictions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6937?source=see_link\">",
"     \"Uremic pruritus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36325?source=see_link\">",
"     \"Muscle cramps in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned, pain is the most frequently reported symptom in the dying patient with chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. Moreover, pain remains undertreated in many hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This is particularly the case when patients die in an institution versus the home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/32,33,35\">",
"     32,33,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of specific analgesics in this patient population must be guided by the observation that, because of impaired renal excretion, many such agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their breakdown proteins accumulate in those with renal disease, resulting in significant adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    should not be used in those with chronic kidney dysfunction because its metabolite, normeperidine, accumulates, leading to central nervous system excitability and seizures. Similarly, prolonged use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    in patients with chronic kidney disease may lead to the accumulation of morphine-3-glucuronide and morphine-6-glucuronide, which may contribute to the development of myoclonic jerks (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H11#H11\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Myoclonus'",
"    </a>",
"    ). The accumulation of morphine-6-glucuronide may also lead to prolonged narcosis in those with kidney disease. However, for short term use (days), morphine is an excellent analgesic for dying patients with end stage renal disease and is also useful in the treatment of dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/1,38\">",
"     1,38",
"    </a>",
"    ]. In general, it is recommended that morphine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    be avoided in dialysis patients, that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    be used with caution, and that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    appear to be relatively safe to use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The World Health Organization pain ladder is an effective tool in the management of pain in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link&amp;anchor=H19#H19\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Use in renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation almost invariably occurs with the use of opiates. Thus, stool softeners, dietary measures, and laxatives should be used when needed. When opiates are prescribed,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    sodium 100 mg po twice daily",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    should be started. For constipation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     g/15",
"    </span>",
"    mL syrup) 15 to 30 mL po once or twice daily or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    30 mg po or 10 mg rectal suppository once daily are usually effective. Saline enemas or glycerine rectal suppositories may also be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link&amp;anchor=H24#H24\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Rectal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Myoclonus, muscle twitching, and seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously noted, myoclonus and muscle twitching may occur with the use of opioids, as well as agitation and confusion. Drug-induced or uremic-associated muscle twitching or myoclonus may be treated with benzodiazepines, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benzodiazepines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    are also useful in treating anxiety.",
"   </p>",
"   <p>",
"    Less than 10 percent of patients who withdraw from dialysis develop seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, the routine, prophylactic use of anticonvulsants is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypervolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of volume overload are uncommon in patients who withdraw from dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. Patients should be instructed to carefully limit fluid and sodium intake. As an alternative, some clinicians advocate the continuation of ultrafiltration alone to permit the liberalization of nutrition and fluid intake in the last week or two of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other symptoms such as nausea and vomiting and delirium may also be treated with medications dosed for the level of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/1,41\">",
"     1,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Post-death assessment and bereavement care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some dialysis programs have begun assessing the quality of a patient's death as part of quality assurance activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36694/abstract/2\">",
"     2",
"    </a>",
"    ]. This promotes examination of the character",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    quality of a patient's death and focuses attention on efforts to ensure establishment of advance care planning, symptom control, and effective communication among interdisciplinary teams, patient, and family. Bereavement support to families and involved care givers (eg, dialysis unit staff, transporters, etc) may be addressed by dialysis unit sponsored memorial services, follow-up calls, and cards of condolence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27722032\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palliative care refers to the comprehensive management of the physical, psychological, social, spiritual, and existential needs of patients within the context of family and community. The goal of palliative care is to achieve the best possible quality of life by relieving suffering, controlling symptoms, and restoring functional capacity, while maintaining sensitivity to personal, cultural, and spiritual beliefs and practices. Palliative care in patients with end-stage renal disease (ESRD) incorporates all members of the interdisciplinary team (physicians, nurses, social workers, peers, families). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Principles of palliative care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Important aspects of palliative care in those with ESRD include assessment of quality of life and prognosis, development of appropriate advance directives through an advance care planning process, symptom control after dialysis discontinuation, morbidity and mortality review of the quality of death, and bereavement care for family and community. Dialysis patients have symptoms (pain, fatigue, and pruritus) that are commonly undertreated. Hospice is underutilized in those with ESRD and should be considered in any patients refusing or withdrawing from dialysis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Quality of life assessment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Advance directives'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptom control after dialysis discontinuation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Post-death assessment and bereavement care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/1\">",
"      Neely KJ, Roxe DM. Palliative care/hospice and the withdrawal of dialysis. J Palliat Med 2000; 3:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/2\">",
"      Cohen LM, Germain M, Poppel DM, et al. Dialysis discontinuation and palliative care. Am J Kidney Dis 2000; 36:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/3\">",
"      Moss AH, Holley JL, Davison SN, et al. Palliative care. Am J Kidney Dis 2004; 43:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/4\">",
"      Levy JB, Chambers EJ, Brown EA. Supportive care for the renal patient. Nephrol Dial Transplant 2004; 19:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/5\">",
"      Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nonagenarians starting dialysis in the United States. Ann Intern Med 2007; 146:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/6\">",
"      Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal palliative care. J Palliat Med 2006; 9:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/7\">",
"      Holley JL. Palliative care in end-stage renal disease: illness trajectories, communication, and hospice use. Adv Chronic Kidney Dis 2007; 14:402.",
"     </a>",
"    </li>",
"    <li>",
"     Renal Physicians Association Clinical Practice Guideline. Shared Decision-Making in the Appropriate Initiation of and Withdrawal from Dialysis, 2nd ed, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/9\">",
"      Douglas C, Murtagh FE, Chambers EJ, et al. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. Palliat Med 2009; 23:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/10\">",
"      Holley JL, Carmody SS, Moss AH, et al. The need for end-of-life care training in nephrology: national survey results of nephrology fellows. Am J Kidney Dis 2003; 42:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/11\">",
"      Davison SN, Jhangri GS, Holley JL, Moss AH. Nephrologists' reported preparedness for end-of-life decision-making. Clin J Am Soc Nephrol 2006; 1:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/12\">",
"      Germain MJ, Cohen L. Supportive care for patients with renal disease: time for action. Am J Kidney Dis 2001; 38:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/13\">",
"      Davison SN. End-of-life care preferences and needs: perceptions of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/14\">",
"      Jassal SV, Watson D. Doc, don't procrastinate...Rehabilitate, palliate, and advocate. Am J Kidney Dis 2010; 55:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/15\">",
"      Cukor D, Kimmel PL. Education and end of life in chronic kidney disease: disparities in black and white. Clin J Am Soc Nephrol 2010; 5:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/16\">",
"      Gunda S, Thomas M, Smith S. National survey of palliative care in end-stage renal disease in the UK. Nephrol Dial Transplant 2005; 20:392.",
"     </a>",
"    </li>",
"    <li>",
"     Task force on Palliative care. Last acts: Precepts of palliative care, Stewart Communications, Ltd., Chicago, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/18\">",
"      Hines SC, Glover JJ, Holley JL, et al. Dialysis patients' preferences for family-based advance care planning. Ann Intern Med 1999; 130:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/19\">",
"      Perry E, Swartz R, Smith-Wheelock L, et al. Why is it difficult for staff to discuss advance directives with chronic dialysis patients? J Am Soc Nephrol 1996; 7:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/20\">",
"      Davison SN. Facilitating advance care planning for patients with end-stage renal disease: the patient perspective. Clin J Am Soc Nephrol 2006; 1:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/21\">",
"      Holley JL, Hines SC, Glover JJ, et al. Failure of advance care planning to elicit patients' preferences for withdrawal from dialysis. Am J Kidney Dis 1999; 33:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/22\">",
"      Singer PA, Martin DK, Lavery JV, et al. Reconceptualizing advance care planning from the patient's perspective. Arch Intern Med 1998; 158:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/23\">",
"      \"Springing back\" advance care planning in dialysis. Am J Kidney Dis 1999; 33:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/24\">",
"      Citko J, Moss AH, Carley M, Tolle S. The National POLST Paradigm Initiative, 2nd Edition #178. J Palliat Med 2011; 14:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/25\">",
"      Kapron K, Perry E, Bowman T, Swartz RD. Peer resource consulting: redesigning a new future. Adv Ren Replace Ther 1997; 4:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/26\">",
"      Berman E, Merz JF, Rudnick M, et al. Religiosity in a hemodialysis population and its relationship to satisfaction with medical care, satisfaction with life, and adherence. Am J Kidney Dis 2004; 44:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/27\">",
"      Song MK, Ward SE, Happ MB, et al. Randomized controlled trial of SPIRIT: an effective approach to preparing African-American dialysis patients and families for end of life. Res Nurs Health 2009; 32:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/28\">",
"      Neu S, Kjellstrand CM. Stopping long-term dialysis. An empirical study of withdrawal of life-supporting treatment. N Engl J Med 1986; 314:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/29\">",
"      Fissell RB, Bragg-Gresham JL, Lopes AA, et al. Factors associated with \"do not resuscitate\" orders and rates of withdrawal from hemodialysis in the international DOPPS. Kidney Int 2005; 68:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/30\">",
"      Soltys FG, Brookins M, Seney J. Why hospice? The case for ESRD patients and their families. ANNA J 1998; 25:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/31\">",
"      Murray AM, Arko C, Chen SC, et al. Use of hospice in the United States dialysis population. Clin J Am Soc Nephrol 2006; 1:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/32\">",
"      Cohen LM, Germain MJ, Woods AL, et al. The family perspective of ESRD deaths. Am J Kidney Dis 2005; 45:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/33\">",
"      Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis 2003; 42:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/34\">",
"      Davison SN. The prevalence and management of chronic pain in end-stage renal disease. J Palliat Med 2007; 10:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/35\">",
"      Bailie GR, Mason NA, Bragg-Gresham JL, et al. Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription. Kidney Int 2004; 65:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/36\">",
"      Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/37\">",
"      Murtagh FE, Chai MO, Donohoe P, et al. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 2007; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/38\">",
"      Cohen MH, Anderson AJ, Krasnow SH, et al. Continuous intravenous infusion of morphine for severe dyspnea. South Med J 1991; 84:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/39\">",
"      Barakzoy AS, Moss AH. Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease. J Am Soc Nephrol 2006; 17:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36694/abstract/40\">",
"      Eibach U, Schaefer K. Support after discontinuation of dialysis--medical and ethical considerations. Nephrol Dial Transplant 1998; 13:1154.",
"     </a>",
"    </li>",
"    <li>",
"     Aronoff, GR, Berns, JS, Brier, ME, et al. Drug prescribing in renal failure, 4th ed, American College of Physicians, Philadelphia, 1999.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1919 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-A90D1A112B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36694=[""].join("\n");
var outline_f35_53_36694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27722032\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF PALLIATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Quality of life assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Advance directives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptom control after dialysis discontinuation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Constipation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Myoclonus, muscle twitching, and seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypervolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Post-death assessment and bereavement care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27722032\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16165?source=related_link\">",
"      Ethical issues in the care of the patient with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=related_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36325?source=related_link\">",
"      Muscle cramps in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6937?source=related_link\">",
"      Uremic pruritus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_53_36695="Mechanisms of pleural liquid accumulation in disease";
var content_f35_53_36695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanisms of pleural liquid accumulation in disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36695/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36695/contributors\">",
"     V Courtney Broaddus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36695/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36695/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36695/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36695/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/53/36695/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal pleural space, there is a steady state in which there is a roughly equal rate of the formation (entry) and absorption (exit) of liquid (",
"    <a class=\"graphic graphic_figure graphicRef62020 \" href=\"mobipreview.htm?4/17/4383\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9735?source=see_link\">",
"     \"Mechanisms of pleural liquid turnover in the normal state\"",
"    </a>",
"    .) This balance must be disturbed in order to produce a pleural effusion. Thus, there must be an increase in entry rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reduction in exit rate. It is likely that both mechanisms contribute to effusion formation for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An isolated increase in entry rate, unless massive, is unlikely to cause a large effusion because the absorbing pleural lymphatics have a large reserve capacity to deal with excess pleural liquid. If, for example, an artificial hydrothorax is instilled into the pleural space of an awake sheep, the exit rate can increase to 0.28",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per h, which is 28 times the baseline rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An isolated decrease in exit rate is also unlikely to cause a large effusion because the normal entry rate is low. Even if the exit of liquid ceased entirely, accumulation of liquid would take many days to become evident. As an example, the normal entry rate of 0.01",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per h is equivalent to a total of 14.4",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      in a 60 kg woman; at this rate, it would take 34 days for 500 mL to accumulate in the pleural space if there were no exit. Of note, the effusion would presumably be a transudate, since the normal entering liquid is low in protein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCREASED FLUID ENTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess liquid filters out of microvessels based on a balance of hydrostatic and osmotic forces across a semipermeable membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These forces are well described in the Starling equation, in which the hydrostatic forces that filter water out of the vessel are balanced by osmotic forces that reabsorb water back into the vessel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &nbsp;Flow &nbsp;= &nbsp;",
"    <strong>",
"     k",
"    </strong>",
"    &nbsp;x &nbsp; [(",
"    <strong>",
"     P",
"    </strong>",
"    mv &nbsp;- &nbsp;",
"    <strong>",
"     P",
"    </strong>",
"    pmv) &nbsp;- &nbsp;s (&pi;mv &nbsp;- &nbsp;&pi;pmv)]",
"   </p>",
"   <p>",
"    In this equation,",
"    <strong>",
"     k",
"    </strong>",
"    is liquid conductance of the microvascular barrier,",
"    <strong>",
"     P",
"    </strong>",
"    mv and",
"    <strong>",
"     P",
"    </strong>",
"    pmv represent hydrostatic pressure in the microvascular and perimicrovascular compartments, s is the reflection coefficient for total protein and ranges from 0 (completely permeable) to 1 (completely impermeable), and &pi;mv and &pi;pmv represent protein osmotic pressure in microvascular and perimicrovascular liquids, respectively. In normal microvessels, there is ongoing filtration of a small amount of low protein liquid. The flow can increase with changes in various parameters of the Starling equation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increase in permeability",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in flow can be due to increases in either liquid conductance (an increase in k) or protein permeability (a decrease in reflection coefficient). If the endothelial barrier becomes more permeable to liquid and protein, for example, there will be an increase in flow of a higher protein liquid. Because absorption does not alter the protein concentration of pleural liquid, pleural liquid with a high protein concentration indicates its origin from a circulation across an area of increased permeability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9735?source=see_link&amp;anchor=H12#H12\">",
"     \"Mechanisms of pleural liquid turnover in the normal state\", section on 'Evidence for bulk flow'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Increase in microvascular pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevation in microvascular pressure (Pmv) is usually induced by an elevation in venous outflow pressure. Increases in arterial pressure are less likely to be transmitted to the microvessels because of the high precapillary resistance and autoregulation of arteriolar tone.",
"   </p>",
"   <p>",
"    Elevations in either systemic venous pressure (affecting the parietal pleura) or pulmonary venous pressure (affecting the visceral pleura) can lead to an increase in pleural liquid formation and the development of a pleural effusion. Vascular permeability is unchanged in this setting; as a result, the increased flow is associated with a greater sieving of proteins, leading to a filtrate with a lower protein concentration than normal (with a pleural liquid-to-plasma protein ratio of less than 0.15).",
"   </p>",
"   <p>",
"    Of course, most effusions formed due to increased microvascular pressures, ie, transudative effusions, have a pleural liquid-to-plasma protein ratio much higher than this, between 0.4 and 0.5. This fact demonstrates that most liquid must arise from a source other than the systemic circulation of the pleural membranes. The likely source is the large non-systemic circulation adjacent to the pleural space, namely the pulmonary circulation of the nearby lung. In the normal state, lung interstitial liquid, eg, lymph, filtered from the low pressure pulmonary circulation has a protein concentration ratio (lung to plasma protein concentration ratio) of 0.7, but with increased flow due to increased pulmonary microvascular pressures, this ratio falls to 0.4-0.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/6\">",
"     6",
"    </a>",
"    ]. This lung interstitial edema liquid then is the likely source of the majority of the hydrostatic pleural effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How does the lung liquid reach the pleural space? When the rate of filtrate formation exceeds the absorptive capacity of the lung lymphatics, the filtrate accumulates in the peribronchovascular spaces (\"cuffs\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/8\">",
"     8",
"    </a>",
"    ]. Once in these interstitial spaces, the liquid is not accessible to lung lymphatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, although the lymphatics are undeniably important in removing liquid as it is filtered from the pulmonary circulation, they cannot account for the clearance of already established edema from the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/10\">",
"     10",
"    </a>",
"    ]. This interstitial edema probably leaves the lung by flowing down pressure gradients along the interstitial spaces (interlobular septae, peribronchovascular bundles and visceral pleura) of the lung toward either the mediastinum or the pleural space. The entry of large amounts of lung interstitial liquid into the pleural space will elevate the overall protein concentration of the pleural liquid, giving a ratio of 0.40-0.50, the expected range for a transudative effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decrease in pleural pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decrease in pleural pressure, as seen with significant atelectasis, may alter the balance of forces described in the Starling equation by reducing the pressures surrounding the nearby microvessels. This decrease in perimicrovascular pressures (",
"    <strong>",
"     P",
"    </strong>",
"    pmv) can enhance filtration across the microvascular barrier of a low protein liquid (with a pleural liquid-to-plasma protein ratio of less than 0.15).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Decrease in plasma osmotic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoproteinemia (due to hypoalbuminemia) will decrease the plasma oncotic pressure (&pi;mv), thereby increasing the forces favoring filtration until the balance is restored. By itself, hypoproteinemia can probably induce small effusions with a low protein concentration. In addition, hypoproteinemia can lower the threshold for effusion formation when other Starling forces are changed. In a study of hospitalized patients with AIDS, for example, hypoproteinemia alone was the apparent cause of 19 percent of all pleural effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/11\">",
"     11",
"    </a>",
"    ]. Together with other factors, a lower plasma protein concentration may have contributed to effusion formation in many more patients, because, in general, all patients with effusions had a lower plasma albumin concentration than those without effusion (2.5 versus 3.4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [25 versus 34",
"    <span class=\"nowrap\">",
"     g/L]).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DECREASED FLUID EXIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    decrease in exit rate reflects a reduction in lymphatic function. Because lymphatic function is poorly understood, much of this discussion is speculative. Unlike blood vessels, lymphatic vessels have one-way valves and propel lymph using both their own rhythmic contractions and the respiratory motions of the chest wall. In addition, flow is affected by lymphatic patency, availability of liquid, and the pressures influencing filling (pleural pressure) and emptying (systemic venous pressure) of lymphatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Intrinsic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors can interfere with or inhibit the ability of lymphatics to contract, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cytokines and products of inflammation (eg, endotoxins)",
"     </li>",
"     <li>",
"      Endocrine abnormalities (eg, hypothyroidism)",
"     </li>",
"     <li>",
"      Injury due to radiation or drugs (eg, chemotherapeutic agents)",
"     </li>",
"     <li>",
"      Infiltration of lymphatics by cancer",
"     </li>",
"     <li>",
"      Anatomic abnormalities (eg, yellow nail syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Extrinsic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple extrinsic factors can inhibit lymphatic function although the lymphatics themselves are normal. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limitation of respiratory motion (eg, diaphragm paralysis, lung collapse, pneumothorax)",
"     </li>",
"     <li>",
"      Extrinsic compression of lymphatics (eg, pleural fibrosis, pleural granulomas)",
"     </li>",
"     <li>",
"      Blockage of lymphatic stomata (eg, fibrin deposition on pleural surface, pleural malignancy)",
"     </li>",
"     <li>",
"      Decreased intrapleural pressure (eg, trapped lung caused by a fibrous rind on the visceral pleura)",
"     </li>",
"     <li>",
"      Increased systemic venous pressure - Acutely, increases in venous pressure may decrease lymphatic flow because of the higher downstream pressures; chronically, the lymphatics may be able to adapt.",
"     </li>",
"     <li>",
"      Decreased liquid availability - After pneumothorax, for example, liquid will be in contact with fewer lymphatic stomata and may accumulate in the pleural space.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EFFUSION FORMATION AND DISEASE STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, no single mechanism is likely to explain the development of a pleural effusion. It is likely that for many effusions, multiple factors contribute to effusion formation. In addition, an alteration of one mechanism can lower the threshold for effusion formation later by another mechanism. Thus, a decreased exit rate due to malignant infiltration of lymphatics can gradually reduce the capacity of the lymphatics to drain pleural liquid. An effusion will not form as long as the entry rate is slow; however, if the entry rate should rise, the limitation of the exit rate would limit the ability of the lymphatic clearance to handle the increased fluid and an effusion could accumulate.",
"   </p>",
"   <p>",
"    There are few data on the entry and exit rates of pleural liquid in patients with pleural effusions. In two early studies of the turnover of pleural liquid in effusions of patients with a variety of different diseases, the entry rates were highest in tuberculosis but similar among the other disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The exit rates were low in malignant and tuberculous effusions compared to the rates in effusions due to cardiac failure and pulmonary embolism. In one study, for example, calculated lymphatic flow for patients with pulmonary embolism was 0.18",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per h, which is similar to the maximal exit rate measured for sheep (0.28",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per h); in comparison, lymphatic flow was lower in the patients with carcinoma or tuberculosis (0.06 and 0.08",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per h, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/15\">",
"     15",
"    </a>",
"    ]. Interestingly, the entry rate decreased and the exit rate increased after therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in patients with tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFUSION FORMATION BY SITE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most effusions form due to changes at the level of the pleural membranes, lungs, mediastinum, or diaphragm. On occasion, effusions can develop from abnormalities in other organs such as the central nervous system, kidney, or pancreas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pleura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct involvement of pleural membranes by disease can lead to a pleural effusion by increasing the formation of liquid and interfering with parietal pleural lymphatic function (",
"    <a class=\"graphic graphic_figure graphicRef54788 \" href=\"mobipreview.htm?3/5/3167\">",
"     figure 2",
"    </a>",
"    ). Hydrostatic pressure elevations can also increase filtration from the pleural membrane microvessels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy &ndash; Malignant effusions are probably caused by both mechanisms, increased entry plus decreased exit of fluid. There are patients with rapid entry rates, which can be recognized clinically because the effusion accumulates rapidly after drainage or has a high chest tube drainage rate. In this setting, the tumor has presumably extensively infiltrated pleural capillaries, leading to increased filtration, or is producing cytokines, such as vascular endothelial growth factor (VEGF), that increase capillary permeability. Decreased plasma osmotic pressure or decreased pleural pressure could contribute to the enhanced entry of liquid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, malignancy may lead to effusion formation by infiltrating the draining lymph nodes, thereby decreasing the exit rate. In some cases of lymphatic involvement, the decrease in the exit rate appears to be an important mechanism of effusion formation because the effusions can resolve after mediastinal irradiation of involved lymph nodes. In certain malignant effusions, extrapleural involvement of draining lymphatics may be the sole mechanism of effusion formation. Such an isolated exit block may explain the existence of transudative effusions in approximately 10 percent of patients with malignant effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculosis &ndash; Tuberculosis involves the pleural membranes with a granulomatous reaction that may lead to both an increased entry rate and decreased exit rate of liquid. The high protein concentration of tuberculous pleural effusions indicates its origin from capillaries involved with an intense inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/15\">",
"       15",
"      </a>",
"      ]. The exit rate, on the other hand, has been found to be low in both patients and animals with experimental models of BCG pleurisy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/14,15,17\">",
"       14,15,17",
"      </a>",
"      ]. The low exit rate may indicate that inflammation of the parietal pleural by tuberculosis is extensive and intense enough to compromise pleural lymphatic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with pleural malignancy or tuberculosis, the synergistic combination of increased entry and decreased exit of liquid may explain the massive effusions that can accumulate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pleural microvessel hydrostatic pressure elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in the microvascular pressure of pleural vessels can increase filtration in a variety of ways. Systemic venous pressure elevation both increases filtration from the parietal pleural microvessels and decreases lymphatic drainage into the venous system (",
"    <a class=\"graphic graphic_figure graphicRef76273 \" href=\"mobipreview.htm?5/14/5359\">",
"     figure 3",
"    </a>",
"    ). In comparison, an elevation in pulmonary venous pressure increases filtration from the visceral pleura.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary embolism &ndash; Pulmonary embolism can increase entry rates of liquid by injuring pulmonary and adjacent pleural systemic circulations, by elevating hydrostatic pressures in pulmonary veins",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      systemic veins, and perhaps by lowering pleural pressure due to atelectasis. Pulmonary embolism may also decrease exit rates of pleural liquid by increasing the systemic venous pressure (thereby hindering lymphatic drainage) or perhaps by decreasing pleural pressure (thereby hindering lymphatic filling). The observation that all effusions due to pulmonary embolism are exudates suggests a key role for vascular injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/18\">",
"       18",
"      </a>",
"      ]; however, hydrostatic pressure changes probably also contribute to the formation of the effusions. As in acute lung injury, when microvessels are injured, small changes in hydrostatic pressure can have a large effect on fluid flux.",
"     </li>",
"     <li>",
"      Superior vena cava syndrome &ndash; The mechanism of effusion formation in patients with the superior vena cava syndrome has only been studied in a few cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/19\">",
"       19",
"      </a>",
"      ]. Apparently, the entry rate of liquid into the pleural space is increased. The most detailed study has been in one patient who was shown to have a transudative effusion with flow through the thoracostomy tube of approximately 500",
"      <span class=\"nowrap\">",
"       mL/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/20\">",
"       20",
"      </a>",
"      ]. In another study of volume-loaded dogs, an elevation in systemic venous pressure for two hours plus a decrease in plasma osmotic pressure led to a significant increase in pleural liquid entry and formation of an effusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exit rate may also be decreased acutely since the lymphatics must pump against a higher downstream pressure. With chronic pressure elevations, however, the lymphatics may adapt and resume a more normal capacity. In a series of 27 patients with chronic systemic venous pressure elevation due to pulmonary hypertension, for example, no effusions were found on ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lung is a potentially large source of liquid immediately adjacent to the pleural space. Lung interstitial liquid can move into the pleural space along a pressure gradient and across leaky pleural membranes (",
"    <a class=\"graphic graphic_figure graphicRef71048 \" href=\"mobipreview.htm?3/20/3407\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute lung injury &ndash; From animal studies in which injury is limited to the lung, it is clear that large amounts of lung liquid can move into the pleural space. After chemical or hyperoxia-induced lung injury in animals, for example, an increased permeability lung edema developed and was followed by high protein pleural effusions in approximately two hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. With hyperoxic lung injury in rats, the movement of liquid from lung to pleural space could be traced by the movement of a specific marker [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/27\">",
"       27",
"      </a>",
"      ]. In sheep given intravenous oleic acid, liquid leaving the lung across the visceral pleura could be collected in a surrounding bag and quantified as representing almost 20 percent of the lung edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that pleural effusions should be common in patients with acute lung injury. In a radiographic study of patients with pulmonary edema, for example, pleural effusions were found to be as common in patients with acute lung injury (36 percent) as in patients with hydrostatic pulmonary edema (40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/28\">",
"     28",
"    </a>",
"    ]. Other lung injuries, such as pneumonia or pulmonary embolism, can also result in effusion formation due to the movement of high protein lung interstitial liquid into the pleural space.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydrostatic pulmonary edema &ndash; In heart failure, in contrast to lung injury, the abnormalities are not limited to the lung; as a result, identification of the source of the pleural liquid is more difficult. An elevation in pulmonary venous and systemic venous pressures should lead to increased filtration from both pleural membranes, decreased absorption via pleural lymphatics, and increased filtration into the lung with movement of lung edema into the pleural space.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies suggest that the contribution of lung edema may be the most important. In an experimental study in which pressures were elevated in the systemic venous, the pulmonary venous, or both circulations, the most liquid appeared after systemic pressure elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/21\">",
"     21",
"    </a>",
"    ]. However, this study lasted only two hours and lung edema takes at least two hours to accumulate and then to flow to the pleural space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/7,24,26\">",
"     7,24,26",
"    </a>",
"    ]. It is therefore likely that the contribution from the lung was not yet evident. The observation in a clinical study of patients with heart failure that the presence of pleural effusions by ultrasound correlated better with elevated pulmonary venous pressures than systemic venous pressures is compatible with the importance of a lung contribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/29\">",
"     29",
"    </a>",
"    ], although a visceral pleural contribution cannot be excluded. A later study of patients with pulmonary hypertension showed that isolated increases in systemic venous pressure, at least when chronic, did not cause edema formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in anesthetized sheep addressed the contribution of the lung (and visceral pleura) more directly by isolating the lung in an impermeable bag [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/7\">",
"     7",
"    </a>",
"    ]. Lung edema was created by volume loading to elevate the pulmonary capillary wedge pressure by 10, 20 or 30 cmH2O. Liquid began to leak from the lung, and by two hours after stable pressure elevation, the lung liquid flow had reached a steady state. The lung liquid had the same protein concentration as lung lymph and interstitial liquid later harvested from peribronchovascular spaces (\"cuffs\"). The amount of liquid flowing from the lung could account for the pleural effusions found in other closed-chest volume loaded sheep. The edema that cleared the lung into the pleural space accounted for almost 23 to 29 percent of all edema formed. Thus, the contribution of the pleural route to edema clearance appears to be similar for hydrostatic edema and for increased permeability edema with acute lung injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/26\">",
"     26",
"    </a>",
"    ]. These observations suggest that the pleural route of edema clearance may be an important additional safety factor protecting against alveolar flooding.",
"   </p>",
"   <p>",
"    The protein concentration in the transudative effusions seen with heart failure also argues strongly that the effusions consist mostly of lung interstitial liquid. As discussed above, liquid derived from increased filtration across systemic vessels would be expected to have a very low protein concentration with a pleura-to-plasma protein concentration ratio of 0.15. However, transudative effusions have a higher protein concentration ratio (approximately 0.40 to 0.50), similar to the ratio in pulmonary filtrate (eg, in lung lymph) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protein concentration of pleural fluid and the",
"    <span class=\"nowrap\">",
"     pleural/serum",
"    </span>",
"    protein concentration ratio can increase with acute diuretic therapy, so that a true transudate may yield indices suggestive of an exudate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Although not all studies have shown a change from transudative to exudative chemistries following diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/33\">",
"     33",
"    </a>",
"    ], this phenomenon must be considered when interpreting pleural chemistries in patients following a significant diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Extrapleural or extrapulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess liquid from any tissue may find its way into the pleural space by moving along pressure gradients, and then either flowing across the leaky mesothelium or across holes or tears in the mediastinal pleura or in the diaphragm.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mediastinum &ndash; Effusions have been described following mediastinal inflammation due to esophageal variceal sclerotherapy and esophageal perforation. Chyle collects in the mediastinum from a break in the thoracic duct and decompresses into the pleural space, producing a chylothorax. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=see_link\">",
"       \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"      </a>",
"      .) Fluid from a pancreatic pseudocyst can also flow via pressure gradients into the mediastinum and then decompress into the pleural space.",
"     </li>",
"     <li>",
"      Diaphragm &ndash; Liquid can cross the diaphragm in several ways. Peritoneal liquid can potentially reach the pleural space by convection across the two mesothelial layers. The effusions with a high amylase content associated with pancreatitis may form in this way. There may also be transmitted inflammation as, for example, if pancreatitis generates an adjacent pleurisy and increased pleural capillary filtration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above mechanisms provide an explanation for slow transfer of liquid across the diaphragm; however, a different mechanism is needed to explain rapid transfer of liquid across the diaphragm. Although some have speculated that liquid might cross the diaphragm via lymphatics, there is no evidence for the existence of direct lymphatic channels connecting the peritoneal and pleural spaces across the diaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In studies in which radiocontrast dye is instilled into the peritoneal space, the dye clearly drains into lymphatics that travel to the mediastinum; no dye enters the pleural space. Therefore, the only likely mechanism for rapid movement of liquid across the diaphragm is through acquired defects in the diaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/37\">",
"     37",
"    </a>",
"    ]. The defects apparently form at points of weakness in the muscular webbing of the diaphragm. Based on observations during video-assisted thoracoscopy (VATS), the defects have various morphologies from blebs to fenestrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36695/abstract/38\">",
"     38",
"    </a>",
"    ]. They may be missed, even on direct inspection of the diaphragm, unless pressure is applied to expand them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most effusions are caused by a combination of increased pleural fluid formation and decreased pleural fluid clearance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Increased fluid entry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The protein concentration of pleural liquid is a clue to its formation since protein concentration is not altered by absorption of pleural liquid via lymphatics. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Increase in permeability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevations in either systemic venous pressure (affecting the parietal pleura) or pulmonary venous pressure (affecting the visceral pleura) can lead to an increase in pleural liquid formation and the development of a pleural effusion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Increase in microvascular pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transudative effusions from heart failure are likely caused by entry of lung edema (lung interstitial fluid) into the pleural space. Interstitial edema probably leaves the lung by flowing down pressure gradients along the interstitial spaces of the lung (interlobular septae, peribronchovascular bundles and visceral pleura) toward either the mediastinum or the pleural space. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Increase in microvascular pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoproteinemia (due to hypoalbuminemia) will decrease the plasma oncotic pressure, thereby increasing the forces favoring filtration. By itself, hypoproteinemia may result in small effusions, but when other Starling forces are changed (eg, increased central venous pressure), hypoproteinemia lowers the threshold for effusion formation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Decrease in plasma osmotic pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A reduction in lymphatic function will decrease the absorption rate of pleural liquid. Impairment in lymphatic function may be caused by intrinsic factors (eg, hypothyroidism, cancer infiltration, yellow nail syndrome) or extrinsic factors (eg, decreased respiratory motion from diaphragmatic paralysis, perilymphatic granulomas or cancer, trapped lung). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Decreased fluid exit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In certain malignant effusions, extrapleural infiltration of draining lymphatics may be the sole mechanism of effusion formation. Such an isolated exit block may explain the existence of transudative effusions in approximately 10 percent of patients with malignant effusions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pleura'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic elevation of right atrial pressure or pulmonary arterial pressure (or both) does not cause pleural fluid accumulation, unless there is concomitant elevation of left atrial and pulmonary arterial wedge pressures. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pleural microvessel hydrostatic pressure elevation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pleural effusions can form from excess liquid generated anywhere in the body (lungs, mediastinum, abdomen, retroperitoneum) that moves toward the subatmospheric pressure of the pleural space and across the leaky mesothelium. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Effusion formation by site'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/1\">",
"      Broaddus VC, Wiener-Kronish JP, Berthiaume Y, Staub NC. Removal of pleural liquid and protein by lymphatics in awake sheep. J Appl Physiol 1988; 64:384.",
"     </a>",
"    </li>",
"    <li>",
"     Staub NC, Wiener-Kronish JP, Albertine KH. Transport through the pleura: physiology of normal liquid and solute exchange in the pleural space, Marcel Dekker, New York 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/3\">",
"      Lai-Fook SJ. Pleural mechanics and fluid exchange. Physiol Rev 2004; 84:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/4\">",
"      Starling EH. On the Absorption of Fluids from the Connective Tissue Spaces. J Physiol 1896; 19:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/5\">",
"      Staub NC. Pulmonary edema. Physiol Rev 1974; 54:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/6\">",
"      Erdmann, AJ, Vaughan, TR, Brigham, KL, et al. Effect of increased vascular pressure on lung fluid balance in unanesthetized sheep. Circ Res 1975; 37:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/7\">",
"      Broaddus VC, Wiener-Kronish JP, Staub NC. Clearance of lung edema into the pleural space of volume-loaded anesthetized sheep. J Appl Physiol 1990; 68:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/8\">",
"      Staub NC, Nagano H, Pearce ML. Pulmonary edema in dogs, especially the sequence of fluid accumulation in lungs. J Appl Physiol 1967; 22:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/9\">",
"      Gee MH, Havill AM. The relationship between pulmonary perivascular cuff fluid and lung lymph in dogs with edema. Microvasc Res 1980; 19:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/10\">",
"      Mackersie RC, Christensen J, Lewis FR. The role of pulmonary lymphatics in the clearance of hydrostatic pulmonary edema. J Surg Res 1987; 43:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/11\">",
"      Joseph J, Strange C, Sahn SA. Pleural effusions in hospitalized patients with AIDS. Ann Intern Med 1993; 118:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/12\">",
"      Quick CM, Venugopal AM, Dongaonkar RM, et al. First-order approximation for the pressure-flow relationship of spontaneously contracting lymphangions. Am J Physiol Heart Circ Physiol 2008; 294:H2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/13\">",
"      Hosking B, Makinen T. Lymphatic vasculature: a molecular perspective. Bioessays 2007; 29:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/14\">",
"      STEWART PB. The rate of formation and lymphatic removal of fluid in pleural effusions. J Clin Invest 1963; 42:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/15\">",
"      Leckie WJ, Tothill P. Albumin turnover in pleural effusions. Clin Sci 1965; 29:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/16\">",
"      Sahn SA. Malignant pleural effusions. Clin Chest Med 1985; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/17\">",
"      Apicella MA, Allen JC. A physiologic differentiation between delayed and immediate hypersensitivity. J Clin Invest 1969; 48:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/18\">",
"      Porcel JM, Madro&ntilde;ero AB, Pardina M, et al. Analysis of pleural effusions in acute pulmonary embolism: radiological and pleural fluid data from 230 patients. Respirology 2007; 12:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/19\">",
"      Rice TW. Pleural effusions in superior vena cava syndrome: prevalence, characteristics, and proposed pathophysiology. Curr Opin Pulm Med 2007; 13:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/20\">",
"      Good JT Jr, Moore JB, Fowler AA, Sahn SA. Superior vena cava syndrome as a cause of pleural effusion. Am Rev Respir Dis 1982; 125:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/21\">",
"      Mellins RB, Levine OR, Fishman AP. Effect of systemic and pulmonary venous hypertension on pleural and pericardial fluid accumulation. J Appl Physiol 1970; 29:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/22\">",
"      Wiener-Kronish JP, Goldstein R, Matthay RA, et al. Lack of association of pleural effusion with chronic pulmonary arterial and right atrial hypertension. Chest 1987; 92:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/23\">",
"      Wiener-Kronish JP, Broaddus VC. Interrelationship of pleural and pulmonary interstitial liquid. Annu Rev Physiol 1993; 55:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/24\">",
"      RICHTER CP. The physiology and cytology of pulmonary edema and pleural effusion produced in rats by alpha-naphthyl thiourea (ANTU). J Thorac Surg 1952; 23:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/25\">",
"      Miller KS, Harley RA, Sahn SA. Pleural effusions associated with ethchlorvynol lung injury result from visceral pleural leak. Am Rev Respir Dis 1989; 140:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/26\">",
"      Wiener-Kronish JP, Broaddus VC, Albertine KH, et al. Relationship of pleural effusions to increased permeability pulmonary edema in anesthetized sheep. J Clin Invest 1988; 82:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/27\">",
"      Bernaudin JF, Theven D, Pinchon MC, et al. Protein transfer in hyperoxic induced pleural effusion in the rat. Exp Lung Res 1986; 10:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/28\">",
"      Aberle DR, Wiener-Kronish JP, Webb WR, Matthay MA. Hydrostatic versus increased permeability pulmonary edema: diagnosis based on radiographic criteria in critically ill patients. Radiology 1988; 168:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/29\">",
"      Wiener-Kronish JP, Matthay MA, Callen PW, et al. Relationship of pleural effusions to pulmonary hemodynamics in patients with congestive heart failure. Am Rev Respir Dis 1985; 132:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/30\">",
"      PILLAY VK. TOTAL PROTEINS IN SEROUS FLUIDS IN CARDIAC FAILURE. S Afr Med J 1965; 39:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/31\">",
"      Chakko SC, Caldwell SH, Sforza PP. Treatment of congestive heart failure. Its effect on pleural fluid chemistry. Chest 1989; 95:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/32\">",
"      Romero-Candeira S, Fern&aacute;ndez C, Mart&iacute;n C, et al. Influence of diuretics on the concentration of proteins and other components of pleural transudates in patients with heart failure. Am J Med 2001; 110:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/33\">",
"      Shinto RA, Light RW. Effects of diuresis on the characteristics of pleural fluid in patients with congestive heart failure. Am J Med 1990; 88:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/34\">",
"      Broaddus VC. Diuresis and transudative effusions--changing the rules of the game. Am J Med 2001; 110:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/35\">",
"      Shinohara H, Kominami R, Taniguchi Y, Yasutaka S. The distribution and morphology of lymphatic vessels on the peritoneal surface of the adult human diaphragm, as revealed by an ink-absorption method. Okajimas Folia Anat Jpn 2003; 79:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/36\">",
"      Grimaldi A, Moriondo A, Sciacca L, et al. Functional arrangement of rat diaphragmatic initial lymphatic network. Am J Physiol Heart Circ Physiol 2006; 291:H876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/37\">",
"      Lieberman FL, Hidemura R, Peters RL, Reynolds TB. Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med 1966; 64:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36695/abstract/38\">",
"      Huang PM, Chang YL, Yang CY, Lee YC. The morphology of diaphragmatic defects in hepatic hydrothorax: thoracoscopic finding. J Thorac Cardiovasc Surg 2005; 130:141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6701 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36695=[""].join("\n");
var outline_f35_53_36695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCREASED FLUID ENTRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increase in permeability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Increase in microvascular pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decrease in pleural pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Decrease in plasma osmotic pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DECREASED FLUID EXIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Intrinsic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Extrinsic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EFFUSION FORMATION AND DISEASE STATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFUSION FORMATION BY SITE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pleura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pleural microvessel hydrostatic pressure elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Extrapleural or extrapulmonary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6701\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6701|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/17/4383\" title=\"figure 1\">",
"      Pleural liquid turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/5/3167\" title=\"figure 2\">",
"      Pleural fluid in pleurisy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/14/5359\" title=\"figure 3\">",
"      Pleural fluid venous pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/20/3407\" title=\"figure 4\">",
"      Interstitial pulmonary edema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9735?source=related_link\">",
"      Mechanisms of pleural liquid turnover in the normal state",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_53_36696="Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia";
var content_f35_53_36696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36696/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36696/contributors\">",
"     Glenn R Cunningham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36696/contributors\">",
"     Dov Kadmon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36696/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36696/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36696/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36696/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/53/36696/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign prostatic hyperplasia (BPH) is a common disorder that increases in frequency progressively with age in men older than 50 years (",
"    <a class=\"graphic graphic_figure graphicRef55614 \" href=\"mobipreview.htm?27/51/28477\">",
"     figure 1",
"    </a>",
"    ). The clinical manifestations and the diagnostic approach to patients suspected of having BPH will be reviewed here. The epidemiology, pathogenesis and treatment of this disorder, and lower urinary tract symptoms in men and acute urinary retention are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34104?source=see_link\">",
"     \"Epidemiology and pathogenesis of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35912?source=see_link\">",
"     \"Acute urinary retention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of BPH are lower urinary tract symptoms (LUTS) that include increased frequency of urination, nocturia, hesitancy, urgency, and weak urinary stream. These symptoms typically appear slowly and progress gradually over a period of years. However, they are not specific for BPH. Furthermore, the correlation between symptoms and the presence of prostatic enlargement on rectal examination or by transrectal ultrasonographic assessment of prostate size is poor. This discrepancy probably results from changes in bladder function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/1\">",
"     1",
"    </a>",
"    ] that occur with aging and from enlargement of the transitional zone of the prostate that is not always evident on rectal examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of BPH is becoming better understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/2\">",
"     2",
"    </a>",
"    ]. In population-based studies, the prevalence of moderate to severe lower urinary tract symptoms (LUTS) and decreased peak urinary flow rates increases with age, and there is a modest correlation among LUTS, peak flow rates, and prostate volume. Longitudinal studies have shown only modest increases in the American Urologic Association (AUA) Symptom Index scores. These surrogate measures of BPH suggest a continuum of disease severity and not a threshold effect.",
"   </p>",
"   <p>",
"    In a small percentage of men, untreated BPH can cause acute urinary retention, recurrent urinary tract infections, hydronephrosis, and even renal failure. It is estimated that a 60 year old man with moderate to severe symptoms would have a 13.7 percent chance of developing acute urinary retention in the following 10 years.",
"   </p>",
"   <p>",
"    The natural history of BPH has been examined both in population-based studies and by looking at outcomes in the placebo arms of clinical trials. However, studies have found that outcomes among patients in the placebo arms of clinical trials may not accurately reflect outcomes in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/3\">",
"     3",
"    </a>",
"    ]. In clinical trials, measurements of LUTS and peak urine flow tend to show a regression to the mean; whereas, this is not seen with measurements of prostate volume and PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Population based studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The community-based Olmstead County, Minnesota, study evaluated a random sample of 477 white men aged 40 to 79 years with no previous prostate surgery or prostate cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/5\">",
"       5",
"      </a>",
"      ]. Men with prostate volumes above 50 mL were more likely to have moderate to severe symptoms of BPH, adjusted for age (OR 3.5, 95% CI 1.6-7.5). Based upon the clinician's diagnosis in the medical record, the annual incidence of new diagnoses of BPH in Olmsted County increased from 727 per 100,000 men in 1987 to 1212 in 1992 and then decreased to 546 in 1997 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/6\">",
"       6",
"      </a>",
"      ]. The rise in incidence prior to 1992 is attributed to widespread introduction of PSA determinations and prostate screening in the United States, and part of the fall since then may be related to individuals being diagnosed at an earlier stage in the previous years. Although the Olmsted County study was a population-based prospective study, most of the men were white. It is unclear whether the results translate to other racial and ethnic groups.",
"     </li>",
"     <li>",
"      The Massachusetts Male Aging Study evaluated men 40 to 70 years of age in communities surrounding Boston and assessed them for the prevalence of BPH for the periods between 1987 and 1989 and 1995 and 1997 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/7\">",
"       7",
"      </a>",
"      ]. This study primarily involved white men. Patients were considered to have BPH if they had frequent or difficult urination and had been told by a health professional that they had an enlarged prostate, or if they had undergone surgery for BPH. The overall prevalence of BPH was 19.4 percent in men over age 38.",
"     </li>",
"     <li>",
"      A study from the Nationwide Inpatient Sample, which samples community hospitals in the United States, found that the age-adjusted prevalence of BPH as a primary diagnosis decreased from 0.88 to 0.48 percent from 1998 to 2008 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/8\">",
"       8",
"      </a>",
"      ]. Discharges for BPH surgery decreased 51 percent and discharges for primary BPH with acute renal failure increased more than 400 percent. There were no significant changes in discharges for primary BPH with urinary retention, bladder stones, or urinary infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms need not be progressive. In one study, for example, about one-third of men had a 50 percent reduction in the severity of their symptoms of urinary obstruction when followed with no treatment for 2.5 to 5 years after symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/9\">",
"     9",
"    </a>",
"    ]. On the other hand, many men have progressive disease that eventually requires treatment. In the Olmstead County Study there was a one-point increase in the AUA symptom score over five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/10\">",
"     10",
"    </a>",
"    ]. Peak flow rates decreased approximately 2.1 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/11\">",
"     11",
"    </a>",
"    ], and prostate volume increased about 1.6 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/12\">",
"     12",
"    </a>",
"    ]. In a 30-year prospective study of 1057 men that was reported in 1991, 527 (50 percent) were given a diagnosis of BPH and 110 (10 percent) underwent prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned, the natural history of BPH has also been studied in the placebo arms of clinical trials, although there are concerns that such results may not accurately reflect outcomes in the general population. A systematic review of the placebo arms of 16 randomized trials of medical treatment lasting for one to four years found that the risk of surgery ranged from 1 to 10 percent, and the risk of acute urinary retention (AUR) ranged from 0.4 to 6.0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients experience some progression in symptoms, increase in prostate volume, and decrease in peak urine flow rate that can result in a need for invasive treatment.",
"   </p>",
"   <p>",
"    Age, symptoms, urinary flow rate and prostate volume are risk factors for acute urinary retention at least in population-based studies, though not in all clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/15\">",
"     15",
"    </a>",
"    ]. Men with symptomatic BPH who are not treated have about a 2.5 percent per year risk of developing acute urinary retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Serum PSA is a stronger predictor of prostate growth than age or baseline prostate volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/18\">",
"     18",
"    </a>",
"    ], and therefore PSA should be a good predictor of risk for acute urinary retention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35912?source=see_link\">",
"     \"Acute urinary retention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A population-based study followed 1688 men 50 to 75 years of age and found that prostate volume was associated with age and prior prostate volume over a period of 4.2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/19\">",
"     19",
"    </a>",
"    ]. This allowed prediction of 'normal' prostate volume using age and prostate volume history. The authors suggest that it may be possible to use a model to identify men who should be treated and those who can be followed without treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPH is not believed to be a risk factor for prostate cancer, although studies have come to conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/20\">",
"     20",
"    </a>",
"    ]. BPH occurs primarily in the central or transitional zone of the prostate, while prostate cancer originates primarily in the peripheral part of the prostate. Determining a causal association between BPH and prostate cancer is difficult because both diseases are common in older men and because BPH may increase the likelihood of a patient being tested for prostate cancer. However, an analysis from the placebo arm of the Prostate Cancer Prevention Trial, where routine biopsies were performed, did not find an association between BPH and an increased risk of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before one concludes that a man's symptoms are caused by BPH, other disorders that can cause similar symptoms should be excluded by history, physical examination, and several simple tests. These disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urethral stricture",
"     </li>",
"     <li>",
"      Bladder neck contracture",
"     </li>",
"     <li>",
"      Carcinoma of the prostate",
"     </li>",
"     <li>",
"      Carcinoma of the bladder",
"     </li>",
"     <li>",
"      Bladder calculi",
"     </li>",
"     <li>",
"      Urinary tract infection and prostatitis",
"     </li>",
"     <li>",
"      Neurogenic bladder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical guidelines were developed by the Agency for Health Care Policy and Research, including a standardized questionnaire and recommendations regarding the evaluation of men with symptoms of bladder outlet obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/22\">",
"     22",
"    </a>",
"    ]. The American Urologic Association (AUA) updated these guidelines in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/23\">",
"     23",
"    </a>",
"    ], which recommended optional steps for diagnosing and treating lower urinary tract symptoms (LUTS). The European Association of Urology (EAU) also has developed guidelines with recommended and optional evaluations, and they differ somewhat from those of the AUA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history may provide important diagnostic information. In addition to questioning the man about obstructive urinary symptoms, it is important to ask about the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of type 2 diabetes, which can cause nocturia and is a risk factor for BPH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Symptoms of neurologic disease that would suggest a neurogenic bladder",
"     </li>",
"     <li>",
"      Sexual dysfunction, which is correlated with LUTS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      General health and fitness for possible surgical procedures",
"     </li>",
"     <li>",
"      Gross hematuria or pain in the bladder region suggestive of a bladder tumor or calculi",
"     </li>",
"     <li>",
"      History of urethral trauma, urethritis, or urethral instrumentation that could lead to urethral stricture",
"     </li>",
"     <li>",
"      Family history of BPH and prostate cancer",
"     </li>",
"     <li>",
"      Treatment with drugs that can impair bladder function (anticholinergic drugs) or increase outflow resistance (sympathomimetic drugs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The EAU recommends a 24-hour voiding chart with assessment of frequency and volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower urinary tract symptoms in men are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     American Urologic Association symptom score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AUA symptom score was developed to measure outcomes in studies of different treatments for BPH (",
"    <a class=\"graphic graphic_table graphicRef57680 \" href=\"mobipreview.htm?21/50/22317\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/30\">",
"     30",
"    </a>",
"    ]. It should be used to assess the severity of symptoms of BPH, but not for differential diagnosis. It consists of seven questions: frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying and urgency, each of which is scored on a scale of 0 (not present) to 5 (almost always present). Symptoms are classified as mild (total score 0 to 7), moderate (total score 8 to 19) and severe (total score 20 to 35).",
"   </p>",
"   <p>",
"    The AUA symptom score is a useful way to assess symptoms over time in a relatively quantitative way. In one study, for example, the mean score decreased from 17.6 to 7.1 in four weeks in a group of men who underwent transurethral prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/30\">",
"     30",
"    </a>",
"    ]. Individual men answer the questions in a reproducible way, and the results appear to be valid when the questionnaire is administered by an interviewer to visually impaired and illiterate men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/31\">",
"     31",
"    </a>",
"    ]. However, it correlates poorly with prostate size and peak urinary flow rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The International Prostate Symptom Score (IPSS) uses the same questions and scale as the AUA symptom score and adds a disease-specific quality of life question: \"If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It also has been shown that a voiding diary that includes nocturia, diuria and void volume may provide more meaningful information of prostate volume and maximum urinary flow rates than AUA symptom score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A digital rectal examination should be done to assess prostate size (normal prostate size between 7 to 16 grams, with an average of 11 grams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/36\">",
"     36",
"    </a>",
"    ]) and consistency and to detect nodules, induration, and asymmetry, all of which raise suspicion for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .) Rectal sphincter tone should be determined, and a neurological examination performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283131542\">",
"    <span class=\"h1\">",
"     RECOMMENDED TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Urologic Association (AUA) recommends an urinalysis and a serum PSA for the routine management of patients with LUTS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/23\">",
"     23",
"    </a>",
"    ]. We also obtain a serum creatinine for assessing renal function and evaluate for possible urinary obstruction. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinalysis should be obtained to detect the presence of urinary infection or blood; the latter could indicate bladder cancer or calculi. It is unclear whether benign hematuria is more common in patients with BPH than in age-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, the presence of BPH should not dissuade the clinician from further evaluation of hematuria, particularly since older men are more likely to have serious disorders such as cancer of the prostate or bladder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among those with gross hematuria in whom no cause other than BPH can be identified,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    often suppresses the hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469112836\">",
"    <span class=\"h2\">",
"     Serum creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Urologic Association (AUA) does not recommend obtaining a serum creatinine in the routine management of patients with BPH, however, we generally obtain a serum creatinine as part of routine assessment. The EAU considers this a cost-effective test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/24\">",
"     24",
"    </a>",
"    ]. A high serum creatinine may be due to bladder outlet obstruction or to underlying renal or prerenal disease; it also increases the risk for complications and mortality after prostatic surgery. Ultrasonography of the bladder, ureters and kidneys is indicated if the serum creatinine concentration is high. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ultrasonography and plain abdominal x-rays'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum prostate specific antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer can cause obstructive symptoms, although the presence of symptoms is not predictive of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/31\">",
"     31",
"    </a>",
"    ]. Measurements of serum PSA may be used as a screening test for prostate cancer in these men with BPH, preferably in men between the ages of 50 to 69 years and before therapy for BPH is discussed. Measurement of PSA is recommended by the EAU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/24\">",
"     24",
"    </a>",
"    ]. The following points should be kept in mind when serum PSA determinations are ordered and the results interpreted (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The specificity of the serum PSA assay is lower in men with obstructive symptoms than in asymptomatic men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/41\">",
"       41",
"      </a>",
"      ]. In men with prostate enlargement, the serum PSA value and prostate volume have a log-linear relationship [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/42,43\">",
"       42,43",
"      </a>",
"      ], but there are conflicting data on its utility for predicting development of LUTS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. Older men tend to have a steeper rate of increase in prostate volume with increasing serum PSA concentrations. Free PSA appears to have a higher correlation with prostate volume than total PSA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High values occur in men with prostatic diseases other than cancer, including BPH.",
"     </li>",
"     <li>",
"      Some men with prostatic cancer have serum PSA concentrations of 4.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (a widely used cut-off value) or less. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=see_link&amp;anchor=H7#H7\">",
"       \"Screening for prostate cancer\", section on 'Effect of lowering PSA cutoffs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A combination of digital rectal examination and serum PSA determination provides the most acceptable means for excluding prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283131578\">",
"    <span class=\"h1\">",
"     OPTIONAL TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other tests may be performed as part of the evaluation of men with BPH, however, the American Urologic Association (AUA) considers them optional. Maximal urinary flow rate, post-void residual urine volume, and urine cytology are useful in most men with suspected BPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maximal urinary flow rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maximal urinary flow rates greater than 15",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    are thought to exclude clinically important bladder outlet obstruction. Maximal flow rates below 15",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    are compatible with obstruction due to prostatic or urethral disease; however, this finding is not diagnostic since a low flow rate can also result from bladder decompensation. To reduce the variability in flow rates, the voided volume should be more than 150 mL. A prevoid bladder volume of &gt; 250 mL with a bladder scan can help to insure that the void volume is &gt; 150 mL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/47\">",
"     47",
"    </a>",
"    ]. Among men with BPH, those with maximal flow rates less than 10",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    have better outcomes after surgical intervention than those with higher flow rates. Uroflowmetry is recommended by the EAU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Post-void residual urine volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residual urine volume can be determined by in-out catheterization, radiographic methods, or ultrasonography. The bladder scanner, which can be used in an office, has made this measurement simple because it does not require catheterization or radiologic assistance. Normal men have less than 12 mL of residual urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition to being a possible indicator of BPH, a large residual volume is probably associated with increased risk of infection and is a precursor to bladder decompensation. Measurement of the post-void residual urine volume is recommended by the EAU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, large post-void residual urine volumes were considered to indicate the presence of severe BPH requiring surgery; however, outcome studies supporting this view are lacking. A Veterans Administration Cooperative Study comparing transurethral prostatic resection and watchful waiting in 556 men with moderate symptoms of BPH demonstrated that post-void residual urine volume was not a predictor of surgical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283131625\">",
"    <span class=\"h2\">",
"     Urine cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine cytology may be helpful in men with predominantly irritative symptoms. It may be considered in men with a smoking history, since this is a risk factor for bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Cigarette smoke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H283131653\">",
"    <span class=\"h1\">",
"     NOT RECOMMENDED TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"    </strong>",
"    American Urologic Association does not recommend the following tests in routine evaluation of BPH. However, they may be useful in individual cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pressure-flow studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the pressure in the bladder during voiding provides the most accurate means for determining bladder outlet obstruction; however, this requires either transvesical or transurethral insertion of a catheter into the bladder. In a study of 108 men with obstructive symptoms in whom urine flow rates were measured and pressure-flow studies done, only three percent of those with maximal flow rates below 12",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    were misclassified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/50\">",
"     50",
"    </a>",
"    ]. This test is usually reserved for men with urinary symptoms and maximal flow rates above 15",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    and those in whom the clinical manifestations are atypical and there is reason to suspect some problem other than or in addition to BPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Urethrocystoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethrocystoscopy is not recommended for routine evaluation. It can be useful in detecting calculi, urethral stricture, and bladder cancer. Some urologists routinely perform urethrocystoscopy to assist in planning for surgical therapy of men with BPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Intravenous urography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large number of normal tests (70 to 75 percent) and low rate of detection of abnormalities that change treatment has reduced the frequency with which intravenous urography is performed in men with obstructive and irritative symptoms. In one report, for example, only two to three percent of men had findings that changed treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/51\">",
"     51",
"    </a>",
"    ]. Hematuria, a history of renal stones, urinary tract infection, or previous urinary tract surgery are indications for intravenous urography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ultrasonography and plain abdominal x-rays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is useful in men who have a high serum creatinine concentration or a urinary tract infection. It can be coupled with plain x-rays of the kidneys, ureters, and bladder. If a bladder calculus is diagnosed, it should be considered the result of bladder outlet obstruction until proven otherwise.",
"   </p>",
"   <p>",
"    Despite the fact that BPH occurs in the central or transitional zone of the prostate, ultrasound measurements of central zone volume do not appear to correlate better with lower urinary tract symptoms than measurements of total prostate volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Total prostate volume can be measured by ultrasonography to assess disease progression, and it is useful when considering medical treatment with a 5-alpha-reductase inhibitor or when considering surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/44,53\">",
"     44,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When prostate volume was compared with enucleated prostate weight in men with BPH undergoing open prostatectomy, transurethral ultrasound slightly underestimated volume by 4.4 percent (95% CI, 1.7-10.5), while transabdominal ultrasound overestimated volume by 55.7 percent (95% CI, 31.8-79.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/54\">",
"     54",
"    </a>",
"    ]. This information may be helpful in interpreting different types of ultrasound in order to determine which patients should have open prostatectomies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Newer technologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;It also is possible that newer imaging modalities, such as contrast-enhanced MRI and MR diffusion will be able to differentiate glandular-ductal versus stromal-low ductal tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36696/abstract/55\">",
"     55",
"    </a>",
"    ]. Such information may aid in the detection of cancer and its grading. It is still unclear whether this information will prove to be cost-effective.",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/21/15698?source=see_link\">",
"       \"Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"       \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations of benign prostatic hyperplasia (BPH) are lower urinary tract symptoms (LUTS) that include increased frequency of urination, nocturia, hesitancy, urgency, and weak urinary stream. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of BPH is becoming more clearly understood. Age, LUTS, PSA, prostate volume, and peak flow rates can help predict progression of BPH. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      History, physical examination, and laboratory tests can provide reasonable certainty of the diagnosis. Urinalysis should be done and serum creatinine and PSA should be measured in all patients with lower urinary tract symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H283131542\">",
"       'Recommended tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American Urologic Association symptom score (assessing for frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying, and urgency) is useful for quantifying the patient's symptoms after the diagnosis of BPH has been made. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'American Urologic Association symptom score'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurements of maximal urinary flow rate, post-void residual urine, and urine cytology are optional, but are useful in most men. The performance of other tests (pressure-flow studies, urethrocystoscopy, intravenous urography, ultrasonography, and abdominal x-rays) should be reserved for unusual patients and for those being considered for invasive treatments. (See",
"      <a class=\"local\" href=\"#H283131578\">",
"       'Optional tests'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/1\">",
"      Madersbacher S, Pycha A, Klingler CH, et al. The International Prostate Symptom score in both sexes: a urodynamics-based comparison. Neurourol Urodyn 1999; 18:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/2\">",
"      Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001; 58:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/3\">",
"      Roberts RO, Lieber MM, Jacobson DJ, et al. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc 2005; 80:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/4\">",
"      Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int 2006; 97 Suppl 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/5\">",
"      Girman CJ, Jacobsen SJ, Guess HA, et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/6\">",
"      Sarma AV, Jacobson DJ, McGree ME, et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 2005; 173:2048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/7\">",
"      Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/8\">",
"      Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int 2012; 109:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/9\">",
"      Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl 1990; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/10\">",
"      Jacobsen SJ, Bergstralh EJ, Katusic SK, et al. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology 1998; 52:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/11\">",
"      Roberts RO, Jacobsen SJ, Jacobson DJ, et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000; 163:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/12\">",
"      Rhodes T, Girman CJ, Jacobsen SJ, et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999; 161:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/13\">",
"      Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging. Urology 1991; 38:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/14\">",
"      Emberton M, Fitzpatrick JM, Garcia-Losa M, et al. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 2008; 102:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/15\">",
"      O'Leary MP, Wei JT, Roehrborn CG, et al. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int 2008; 101:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/16\">",
"      Barry M, Roehrborn C. Management of benign prostatic hyperplasia. Annu Rev Med 1997; 48:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/17\">",
"      Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/18\">",
"      Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/19\">",
"      Bosch JL, Tilling K, Bohnen AM, et al. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men. Prostate 2007; 67:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/20\">",
"      Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/21\">",
"      Schenk JM, Kristal AR, Arnold KB, et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol 2011; 173:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/22\">",
"      McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin 1994; :1.",
"     </a>",
"    </li>",
"    <li>",
"     www.auanet.org/guidelines/bph.cfm (Accessed on December 20, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/24\">",
"      Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/25\">",
"      Wilt TJ, N'Dow J. Benign prostatic hyperplasia. Part 1--diagnosis. BMJ 2008; 336:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/26\">",
"      Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/27\">",
"      Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/28\">",
"      Vallancien G, Emberton M, Harving N, et al. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/29\">",
"      Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int 2005; 96:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/30\">",
"      Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/31\">",
"      Barry MJ, Fowler FJ, Chang Y, et al. The American Urological Association symptom index: does mode of administration affect its psychometric properties? J Urol 1995; 154:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/32\">",
"      Lepor H, Nieder A, Feser J, et al. Total prostate and transition zone volumes, and transition zone index are poorly correlated with objective measures of clinical benign prostatic hyperplasia. J Urol 1997; 158:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/33\">",
"      Kojima M, Naya Y, Inoue W, et al. The American Urological Association symptom index for benign prostatic hyperplasia as a function of age, volume and ultrasonic appearance of the prostate. J Urol 1997; 157:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/34\">",
"      Wadie BS, Ibrahim EH, de la Rosette JJ, et al. The relationship of the International Prostate Symptom Score and objective parameters for diagnosing bladder outlet obstruction. Part I: when statistics fail. J Urol 2001; 165:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/35\">",
"      van Venrooij GE, van Melick HH, Eckhardt MD, Boon TA. Diagnostic and predictive value of voiding diary data versus prostate volume, maximal free urinary flow rate, and Abrams-Griffiths number in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2008; 71:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/36\">",
"      Leissner KH, Tisell LE. The weight of the human prostate. Scand J Urol Nephrol 1979; 13:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/37\">",
"      Mohr DN, Offord KP, Melton LJ 3rd. Isolated asymptomatic microhematuria: a cross-sectional analysis of test-positive and test-negative patients. J Gen Intern Med 1987; 2:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/38\">",
"      Ezz el Din K, Koch WF, de Wildt MJ, et al. The predictive value of microscopic haematuria in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Eur Urol 1996; 30:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/39\">",
"      Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000; 163:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/40\">",
"      Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/41\">",
"      Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med 1997; 126:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/42\">",
"      Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/43\">",
"      Hochberg DA, Armenakas NA, Fracchia JA. Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia. Prostate 2000; 45:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/44\">",
"      Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol 2006; 176:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/45\">",
"      Carter HB, Landis P, Wright EJ, et al. Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? J Urol 2005; 173:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/46\">",
"      Mao Q, Zheng X, Jia X, et al. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. Int Urol Nephrol 2009; 41:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/47\">",
"      Dicuio M, Vesely S, Knutson T, et al. Is it possible to predict post-residual voided urine by bladder scan before uroflowmetry--a useful and timesaving test to reduce the number of non--evaluable uroflow measurements? Arch Ital Urol Androl 2010; 82:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/48\">",
"      DiMare JR, Fish SR, Harper JM, et al. Residual urine in normal male subjects. J Urol 1963; 96:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/49\">",
"      Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/50\">",
"      McLoughlin J, Gill KP, Abel PD, Williams G. Symptoms versus flow rates versus urodynamics in the selection of patients for prostatectomy. Br J Urol 1990; 66:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/51\">",
"      Bundrick TJ, Katz PG. Excretory urography in patients with prostatism. AJR Am J Roentgenol 1986; 147:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/52\">",
"      Corica FA, Jacobsen SJ, King BF, et al. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men. J Urol 1999; 161:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/53\">",
"      Lieber MM, Rhodes T, Jacobson DJ, et al. Natural history of benign prostatic enlargement: long-term longitudinal population-based study of prostate volume doubling times. BJU Int 2010; 105:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/54\">",
"      Stravodimos KG, Petrolekas A, Kapetanakis T, et al. TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? Int Urol Nephrol 2009; 41:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36696/abstract/55\">",
"      Noworolski SM, Vigneron DB, Chen AP, Kurhanewicz J. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging 2008; 26:1071.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6889 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36696=[""].join("\n");
var outline_f35_53_36696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      American Urologic Association symptom score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H283131542\">",
"      RECOMMENDED TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H469112836\">",
"      Serum creatinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H283131578\">",
"      OPTIONAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maximal urinary flow rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Post-void residual urine volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H283131625\">",
"      Urine cytology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H283131653\">",
"      NOT RECOMMENDED TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pressure-flow studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Urethrocystoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intravenous urography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ultrasonography and plain abdominal x-rays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Newer technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6889\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6889|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/51/28477\" title=\"figure 1\">",
"      Prevalence of BPH with age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6889|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/50/22317\" title=\"table 1\">",
"      International Prostate Symptom Score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35912?source=related_link\">",
"      Acute urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34104?source=related_link\">",
"      Epidemiology and pathogenesis of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/21/15698?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_53_36697="Surgical procedures for severe chronic mitral regurgitation";
var content_f35_53_36697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical procedures for severe chronic mitral regurgitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36697/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36697/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36697/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36697/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36697/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36697/contributors\">",
"     Edward Verrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/53/36697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/53/36697/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/53/36697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern management of patients with chronic mitral regurgitation (MR) requires an understanding of multiple factors. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pathophysiology and natural history of the disease",
"     </li>",
"     <li>",
"      The severity of the valvular lesion",
"     </li>",
"     <li>",
"      The presence or absence of atrial fibrillation (AF)",
"     </li>",
"     <li>",
"      The indications for mitral valve repair and mitral valve replacement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only effective treatment is surgical valve repair or valve replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical procedures for severe chronic MR will be reviewed here. The indications for corrective surgery in chronic MR, an overview of the natural history and management of chronic MR, and issues related to mitral valve prolapse, ischemic MR, functional MR, and MR in elderly patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6649?source=see_link\">",
"     \"Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34377?source=see_link\">",
"     \"Valvular heart disease in elderly adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREOPERATIVE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have not been performed comparing medical therapy to surgery in patients with severe chronic MR who meet the indications for corrective surgery. However, symptoms are clearly improved and a survival benefit has been suggested on multivariate analysis in observational studies in which some patients had undergone surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25096?source=see_link\">",
"     \"Indications for corrective surgery in severe chronic primary mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two surgical mitral valve procedures are available for the treatment of chronic MR: valve repair and valve replacement. The choice of procedure depends, at least in part, upon the cause of the MR, the anatomy of the mitral valve, and the functional status of the left ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/4\">",
"     4",
"    </a>",
"    ]. In most patients, mitral valve repair at experienced surgical centers is preferred to mitral valve replacement (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"mobipreview.htm?34/19/35132\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Valve repair versus valve replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Surgical risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective way of stratifying operative risk is by using one of the available validated risk stratification models. As noted above, a variety of factors affect the risk of mortality after aortic valve replacement. The risk models are helpful in the evaluation and counseling of individual patients and planning perioperative care. Models have been developed to estimate risk of in-hospital mortality and complications following mitral or aortic valve surgery with or without coronary artery bypass graft surgery (CABG). These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predicting coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with nonischemic chronic MR requiring surgery also have significant coronary artery disease. The prevalence of coronary disease in patients with degenerative mitral valve",
"    <span class=\"nowrap\">",
"     disease/prolapse",
"    </span>",
"    (the most common cause of nonischemic MR) was evaluated in a study in which routine coronary angiography was performed before surgery in 722 patients (67 percent men, mean age 61 years) who did not have a history of myocardial infarction, ischemic electrocardiographic changes, or angina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/5\">",
"     5",
"    </a>",
"    ]. Obstructive (&ge;50 percent) coronary lesions in one or more major vessels were present in 19 percent of patients.",
"   </p>",
"   <p>",
"    Obstructive coronary lesions are usually revascularized at the time of mitral valve surgery; concurrent bypass surgery typically adds little morbidity or mortality to the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ]. A separate issue, which is discussed elsewhere, is the management of ischemic mitral regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and the 2007 ESC guidelines on the management of valvular heart disease included recommendations for the use of coronary angiography to establish the presence or absence of coronary disease prior to valve surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Assuming that the patient is not hemodynamically unstable, coronary angiography was recommended in patients who have or are suspected to have coronary disease (and who may have ischemic MR) and in those at risk for coronary disease.",
"   </p>",
"   <p>",
"    At risk was defined as men &ge;35 years of age, women &ge;35 years of age with coronary risk factors, and postmenopausal women. A higher age threshold of &ge;45 years was recommended in patients without ischemic symptoms or coronary risk factors in whom MR is due to mitral valve prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ]. This is based upon data from the large observational series cited above in which only 3 of 220 such patients (1.3 percent) had coronary disease and all had single-vessel disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these recommendations, many patients without significant coronary disease will undergo coronary angiography. Better methods are needed to identify patients at low risk.",
"   </p>",
"   <p>",
"    A possible alternative is noninvasive coronary angiography, which may be accomplished using computed tomography (CT) or magnetic resonance imaging. The potential utility these tests as an alternative to conventional selective coronary angiography is discussed separately. Further study is required before this approach can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VALVE REPAIR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Valve repair outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral valve repair procedures, called mitral valvuloplasties, are usually preferred for the surgical treatment of MR. Current mitral valve repair techniques, with use of adjunctive artificial chord replacement and ring annuloplasty (with ring prosthesis such as Carpentier Edwards or Duran ring), have significantly expanded the scope and durability of repair, especially in patients with bileaflet and anterior leaflet prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following discussion is related to valve repair for degenerative MR (mitral valve prolapse and flail leaflet). The outcomes after mitral valve repair for ischemic MR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link&amp;anchor=H18#H18\">",
"     \"Ischemic mitral regurgitation\", section on 'Mitral valve repair versus replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mitral valve repair for degenerative MR has two major benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It preserves all of the functional components of the native valve; as a result, repair is associated with better postoperative ventricular function than seen with valve replacement.",
"     </li>",
"     <li>",
"      It avoids the use of a prosthetic heart valve with its attendant complications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=see_link\">",
"       \"Complications of prosthetic heart valves\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient outcomes after mitral valve repair are excellent at experienced centers. In a review from the Cleveland Clinic of 1072 patients who underwent primary isolated mitral valve repair for MR due to degenerative disease, the in-hospital mortality was 0.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/9\">",
"     9",
"    </a>",
"    ]. In the Mayo series of 1173 patients undergoing mitral valve repair for mitral valve prolapse from 1980 to 1999, 30 day mortality was 0.7 percent, five year mortality was 11.3 percent and ten year mortality was 29.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/8\">",
"     8",
"    </a>",
"    ]. The five year and ten year mortality rates were similar to the expected mortality rates in a normal age-matched population (13.5 percent and 28.4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Recurrent MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent MR, which may require reoperation, is a potential limitation of mitral valve repair. However, with current techniques, in experienced centers, the rate of freedom from reoperation after mitral valve repair is similar to that after mitral valve replacement. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Valve repair versus valve replacement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The frequency of recurrent MR and reoperation are illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review from Leuven, Belgium of 242 patients, the incidence of moderate to severe MR at one month, five years, and seven years was 2, 17, and 32 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/10\">",
"       10",
"      </a>",
"      ]. Surgical techniques associated with a greater risk of recurrent MR included lack of use of an annuloplasty ring, the use of chordal shortening instead of artificial chordae or transposition, and lack of use of a sliding plasty for posterior annulus dilatation.",
"     </li>",
"     <li>",
"      In a review from Toronto of 701 patients, freedom from recurrent moderate or severe MR at 12 years was significantly higher with posterior compared to bileaflet or anterior prolapse (80 versus 67 and 65 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/11\">",
"       11",
"      </a>",
"      ]. The rate of reoperation at 12 years was highest with anterior prolapse (12 versus 4 and 6 percent with posterior and bileaflet prolapse) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Cleveland Clinic experience, freedom from reoperation after 10 years was 93 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/9\">",
"       9",
"      </a>",
"      ]. Reoperation for late mitral valve dysfunction was due to progressive degenerative disease in one-half of these cases. Repair durability was greatest in patients with isolated posterior leaflet prolapse who had posterior leaflet resection and annuloplasty.",
"     </li>",
"     <li>",
"      In the Mayo Clinic experience, the risk of reoperation after mitral valve repair was lower in the second decade of the study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/8\">",
"       8",
"      </a>",
"      ]. For patients undergoing surgery during the 1990s, the linearized risk of reoperation was lowest for isolated posterior leaflet repair (0.50 percent per year), intermediate for bileaflet repair (0.92 percent per year), and highest for anterior leaflet repair (1.64 percent per year), although these rates were not statistically different.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The improvement in durability of anterior leaflet repair in the Mayo experience was attributed to changes in technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/8\">",
"     8",
"    </a>",
"    ]. In the 1980s at the Mayo Clinic, anterior leaflet prolapse was corrected by chordal shortening, chordal transfer, or commissural annuloplasty. In the 1990s, anterior leaflet repair was performed by posterior annuloplasty or insertion of polytetrafluoroethylene (Gore-Tex) neochordae, or limited triangular resection. In the Toronto experience, use of neochordae since the 1990s was cited as the single most important factor in making mitral valve repair feasible in most patients with MR with degenerative disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraoperative transesophageal echocardiography is recommended since it can enhance the success of valve repair and can reliably predict early and late mitral valve dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1,6,12\">",
"     1,6,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42040?source=see_link&amp;anchor=H22#H22\">",
"     \"Transesophageal echocardiography in the evaluation of mitral valve disease\", section on 'Role of intraoperative echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation is an adverse prognostic factor in patients with MR and is associated with worse long-term outcomes after mitral valve repair for degenerative MR. Patients with AF tend to be older and are more likely to have left ventricular dysfunction.",
"   </p>",
"   <p>",
"    There are conflicting data as to whether AF is [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/13\">",
"     13",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/14\">",
"     14",
"    </a>",
"    ] an independent predictor of survival after mitral valve repair. However, patients with AF are at increased risk for mortality due to cardioembolic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/13\">",
"     13",
"    </a>",
"    ]. AF is unlikely to resolve after valve repair alone; as a result, a concurrent atrial fibrillation ablation procedure may be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Percutaneous repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods for percutaneous mitral valve repair to treat MR are under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=see_link&amp;anchor=H22872103#H22872103\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Percutaneous repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible role of percutaneous mitral valve repair in chronic ischemic MR is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link&amp;anchor=H18#H18\">",
"     \"Ischemic mitral regurgitation\", section on 'Mitral valve repair versus replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     VALVE REPAIR VERSUS VALVE REPLACEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Comparison of outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of retrospective studies have demonstrated improved LV function and survival in patients undergoing valve repair compared to valve replacement with or without subvalvular (chordal) preservation (",
"    <a class=\"graphic graphic_figure graphicRef56177 \" href=\"mobipreview.htm?40/56/41869\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/16-24\">",
"     16-24",
"    </a>",
"    ]. In one report, for example, 195 patients undergoing valve repair were compared to 214 undergoing valve replacement for organic MR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/3\">",
"     3",
"    </a>",
"    ]. The following significant benefits were found with valve repair:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower operative mortality &mdash; 2.6 versus 10.3 percent",
"     </li>",
"     <li>",
"      A greater increase in left ventricular ejection fraction",
"     </li>",
"     <li>",
"      Higher overall survival at 10 years &mdash; 68 versus 52 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another cohort study, 625 patients who had undergone valve repair were matched for age, gender, year of surgery, and concomitant CABG to 625 patients who had undergone valve replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/23\">",
"     23",
"    </a>",
"    ]. Mitral valve prolapse was present in approximately 43 percent, rheumatic MR in 26 percent, and ischemic MR in 11 percent. Survival at five years was significantly higher in the valve repair group (82 versus 72 percent with valve replacement). This difference was not seen in the subsets of patients &gt;60 years of age or those undergoing both valve surgery and CABG.",
"   </p>",
"   <p>",
"    In contrast to the last finding, other studies have found improved survival with valve repair compared to valve replacement in patients over age 60 and those undergoing concurrent CABG, although the magnitude of benefit was less than in patients without these characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34377?source=see_link&amp;anchor=H14#H14\">",
"     \"Valvular heart disease in elderly adults\", section on 'Mitral valve repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A survival benefit with valve repair may not be seen in higher risk patients with ischemic MR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link&amp;anchor=H18#H18\">",
"     \"Ischemic mitral regurgitation\", section on 'Mitral valve repair versus replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Reoperation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term rates of reoperation appear to be similar with valve repair and valve replacement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Emory experience of patients undergoing surgery between 1984 and 1997, the rate of reoperation for mitral valve replacement at five years was 6 percent for patients who had undergone mitral valve repair and 4 percent for those who had undergone mitral valve replacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/23\">",
"       23",
"      </a>",
"      ]. However, at the end of ten years, rate of reoperation was lower in the mitral repair patients (22 percent) compared with mitral replacement patients (34 percent).",
"     </li>",
"     <li>",
"      Lower rates of reoperation were noted in a cohort of patient undergoing mitral valve surgery during a slightly later time period. In the Mayo experience for initial repairs in the 1990s, the linearized risk of reoperation after repair of the posterior leaflet (0.5 percent per year) compared favorably to the risk of reoperation after mechanical valve replacement (0.7 percent per year) and all mitral valve replacements (0.7 percent per year) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/8\">",
"       8",
"      </a>",
"      ]. The risk of reoperation following bilateral and anterior leaflet repair were higher (0.92 and 1.64 percent per year) although not statistically different.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower rates of reoperation following mitral valve repair in later series probably reflect the use of more effective anterior leaflet prolapse repair techniques (such as PTFE chordal replacement) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Recurrent MR'",
"    </a>",
"    above.) Other possible explanations for the improvement include other technical advances, greater experience, and earlier patient referral.",
"   </p>",
"   <p>",
"    Based upon such observations, both the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines and the 2007 European Society of Cardiology (ESC) guidelines concluded that mitral valve repair is preferred in the majority of patients with chronic MR and should be performed at centers experienced in this procedure (",
"    <a class=\"graphic graphic_table graphicRef51845 \" href=\"mobipreview.htm?34/19/35132\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Because of the lower risk, surgery can be performed earlier when repair is considered highly likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cause of MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feasibility of mitral valve repair, as opposed to replacement, is related to the anatomic cause of the MR. This was illustrated in a series of 248 patients who underwent surgery for MR at the Mayo Clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral valve prolapse was associated with an operative mortality of 1.7 percent; 90 percent underwent valve repair. The five year survival was 86 percent and the five year rate of heart failure was 13 percent. The risk of recurrent MR is discussed above. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recurrent MR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organic, nonprolapse mitral valve disease (due to rheumatic heart disease, endocarditis, or miscellaneous causes) had a 5.7 percent operative mortality; 63 percent underwent valve repair. The five year survival was 69 percent and the five year rate of heart failure was 16 percent. Issues related to surgery in patients with endocarditis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22297?source=see_link\">",
"       \"Surgery for native valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ischemic or functional MR was associated with a 16 percent operative mortality; 75 percent had valve repair. The five year survival was 50 percent and the five year rate of heart failure was 38 percent. Issues related to ischemic and functional MR are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link\">",
"       \"Ischemic mitral regurgitation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link\">",
"       \"Functional mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Valve anatomy on echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative echocardiography can identify structural features that aid in selection of the appropriate surgical procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Echocardiographic parameters that predict failure of annuloplasty in ischemic mitral regurgitation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link&amp;anchor=H18#H18\">",
"     \"Ischemic mitral regurgitation\", section on 'Mitral valve repair versus replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective study published in 1997, 350 patients who were to undergo mitral valve surgery for MR had preoperative transthoracic and transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/27\">",
"     27",
"    </a>",
"    ]. Repair, rather than replacement, was recommended if the following features were present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limited calcification of the leaflets or annulus",
"     </li>",
"     <li>",
"      Prolapse of less than one-third of either leaflet",
"     </li>",
"     <li>",
"      Pure annular dilatation",
"     </li>",
"     <li>",
"      Valvular perforations",
"     </li>",
"     <li>",
"      Incomplete papillary muscle rupture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repair was less likely to be successful so that replacement was indicated if the following conditions existed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extensive calcification or degeneration of a leaflet or annulus",
"     </li>",
"     <li>",
"      Prolapse of more than one-third of the leaflet tissue",
"     </li>",
"     <li>",
"      Extensive chordal fusion, calcification, or papillary muscle rupture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transthoracic and transesophageal echocardiography were equally accurate in predicting the surgical procedure to be performed. A subsequent study suggested that transesophageal echocardiography was slightly better overall but that the benefit was more pronounced in patients with mediocre transthoracic images or flail leaflets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoperative transesophageal echocardiography is helpful in determining the likelihood of valve repair when this factor would affect the timing of surgical intervention. When surgery is indicated regardless of valve repairability, preoperative transesophageal echocardiography is needed only when the transthoracic images are not diagnostic. In contrast, transesophageal echocardiography is essential in the operating room to better define the anatomy, ensure an adequate repair, and confirm the absence of complications after repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe left ventricular dysfunction are at increased risk of mortality from mitral valve surgery, both in terms of perioperative and long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data comparing valve repair to valve replacement in patients with left ventricular dysfunction are limited. Mitral valve repair has been preferred to replacement in this setting because of the comparable or better survival figures, despite the frequent persistence or recurrence of MR. The data supporting this approach are discussed elsewhere. When valve replacement is required, it is important to preserve the chordal mechanism to preserve or improve LV function and geometry. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link&amp;anchor=H7#H7\">",
"     \"Functional mitral regurgitation\", section on 'Mitral valve repair'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     VALVE REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several issues that must be addressed when valve replacement is considered. These include the choice of a mechanical versus bioprosthetic valve and, if possible, chordal preservation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mechanical versus bioprosthetic valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both mechanical and bioprosthetic valves can be used for replacement of a mitral valve. The major problems associated with mechanical valves are thromboembolism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding from the chronic anticoagulation required to prevent thromboembolism. The primary problem with bioprosthetic valves is limited durability due to valve degeneration, particularly among those &lt;65 years old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Chordal preservation to preserve left ventricular geometry and function should be performed whenever possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Chordal preservation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The outcome with these two types of valves was compared in the Veterans Affairs trial in which 181 patients undergoing single mitral valve replacement were randomly assigned to receive a bioprosthetic (Hancock porcine) or mechanical valve (Bjork-Shiley spherical disc prosthesis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a 15 year follow-up, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All-cause mortality was the same with the mechanical valve and bioprosthesis (81 versus 79 percent); death was valve-related in 44 and 57 percent of cases, respectively",
"     </li>",
"     <li>",
"      Primary valve failure, which occurred mainly in patients less than 65 years of age, was much more common with the bioprosthetic valve (44 versus 4 percent); there was no difference in failure rates in those &ge;65 years.",
"     </li>",
"     <li>",
"      There was a similar incidence of other complications with the two types of valves, including thromboembolism, endocarditis, and valve thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later observational study of 214 patients who were less than 60 years of age at the time of initial mitral valve replacement confirmed the lack of a significant mortality difference between bioprosthetic and mechanical valves at up to 25 years of follow-up (hazard ratio 0.9, 95% CI 0.5-1.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/31\">",
"     31",
"    </a>",
"    ]. The rate of valve reoperation at 20 years was much higher with an initial bioprosthetic valve (84 versus 35 percent).",
"   </p>",
"   <p>",
"    The following recommendations for the selection of a bioprosthetic or mechanical mitral valve were made in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2008 focused update when valve replacement is necessary (",
"    <a class=\"graphic graphic_table graphicRef75650 \" href=\"mobipreview.htm?28/61/29659\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bioprosthetic valves are recommended in patients who cannot or will not take",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or have a clear contraindication to warfarin therapy.",
"     </li>",
"     <li>",
"      Among patients who can take",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , the weight of evidence supports the following approach:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A mechanical valve in patients under age 65 who have long-standing AF.",
"     </li>",
"     <li>",
"      A bioprosthetic valve in patients over 65 years of age.",
"     </li>",
"     <li>",
"      A bioprosthetic valve in patients under age 65 who are in sinus rhythm who choose this valve after a detailed discussion of the risks of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy compared to the likelihood of repeat valve replacement in the future.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines note that selection of the type of valve prosthesis in young women likely to become pregnant is controversial. Mitral repair is preferable whenever possible. While bioprosthetic valves are not as durable as mechanical valves, they do not require anticoagulation (which is problematic during pregnancy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chordal preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valve replacement with excision of the subvalvular apparatus is necessary when there is severe leaflet disease with subvalvular scarring and calcification. This procedure generally has a negative impact on left ventricular function, as shown in both experimental animals and humans; it may be due in part to severing of the chordae tendineae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If possible, valve replacement with preservation of the subvalvular apparatus is preferred (",
"    <a class=\"graphic graphic_figure graphicRef79932 \" href=\"mobipreview.htm?5/22/5476\">",
"     figure 2",
"    </a>",
"    ). This procedure provides a competent valve, preserves the functional components of the subvalvular apparatus, improves left ventricular geometry and long-term function, and produces a better clinical outcome than valve replacement alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/20,34\">",
"     20,34",
"    </a>",
"    ]. In a comparative study, for example, the LVEF decreased from 60 percent preoperatively to 36 percent postoperatively in seven patients who had had chordal transection; in comparison, the preoperative and postoperative ejection fractions were similar (63 and 61 percent) in the eight patients who had chordal preservation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors attributed the improved results with chordal preservation to a smaller LV size that results in lower systolic wall stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. Preservation of LV long axis shortening and an ellipsoid (versus spherical) left ventricular shape may also contribute to more effective left ventricular systolic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/37\">",
"     37",
"    </a>",
"    ]. This can be particularly important in patients with decompensated MR, in whom attempts should be made to avoid or minimize a postoperative decline in ventricular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prosthetic valve-patient mismatch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normalization of pulmonary artery pressure is a goal of mitral valve replacement since even mild pulmonary hypertension can impair exercise capacity and may increase morbidity and mortality. However, the effective orifice area index (EOAI) in prosthetic valves used for mitral valve replacement is often small in relation to body size and may be associated with transvalvular pressure gradients similar to those in mild to moderate mitral stenosis. Thus, prosthetic-patient mismatch (PPM) may contribute to persistent postoperative pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/4,38\">",
"     4,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between PPM and reduced post-operative survival was reported by two single-center retrospective studies from Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]; in contrast, a third study found no relationship between PPM and survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Quebec study of 929 patients who underwent mitral valve replacement, the EOAI was used to define PPM as severe when &le;0.9",
"      <span class=\"nowrap\">",
"       cm2/m2",
"      </span>",
"      (9 percent), moderate (69 percent of patients) when &gt;0.9 and &le;1.2",
"      <span class=\"nowrap\">",
"       cm2/m2,",
"      </span>",
"      and nonsignificant when &gt;1.2",
"      <span class=\"nowrap\">",
"       cm2/m2",
"      </span>",
"      (22 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/39\">",
"       39",
"      </a>",
"      ]. Patients with severe PPM had 6 and 12 year survivals that were lower than those for patients with moderate or nonsignificant PPM (74 versus 84 and 90 percent at six years, and 63 versus 76 and 82 percent at 12 years). PPM was associated with higher pulmonary artery pressures.",
"     </li>",
"     <li>",
"      In the Ottawa study of 884 patients who underwent mitral valve replacement, PPM, defined as an EOAI of &le;1.25",
"      <span class=\"nowrap\">",
"       cm2/m2,",
"      </span>",
"      was present in 32 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/40\">",
"       40",
"      </a>",
"      ]. Survival for patients with PPM was significantly lower compared to those without PPM at all time points ranging from 91 versus 95 percent at one year to 65 versus 75 percent at 10 years.",
"     </li>",
"     <li>",
"      In contrast, a study from Vancouver found no association between PPM and overall mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/41\">",
"       41",
"      </a>",
"      ]. Among 2,440 patients who had undergone mitral valve replacement, 14 percent had no PPM, 70 percent had moderate PPM and 16 percent had severe PPM (categories defined as in the Quebec study). Survival to 15 years was not significantly different among patients with no, moderate, or severe PPM. The EOAI was an independent predictor of early mortality but not of late or overall mortality. There was interaction EOAI and pulmonary hypertension (which was an independent predictor of overall mortality) .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations of these studies included absence of separate results for patients with either mitral regurgitation or stenosis and inclusion of patients who might have undergone mitral valve repair using current practice standards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. There were large differences in the frequency of PPM (78 percent, 32, and 86 percent) in the two studies which may have been partly due to the lower proportion of smaller prostheses in the Ottawa study as well as differing normal reference values for EOA in the two studies.",
"   </p>",
"   <p>",
"    In addition, it is not clear that the association between PPM and pulmonary hypertension is causal. Patients requiring smaller prosthetic valve sizes (eg, &lt; 27 mm) frequently have heavily calcified mitral annuli and longstanding mitral disease likely to predispose to persistent pulmonary hypertension. Therefore PPM may reflect patient specific risk factors rather than a prosthetic valve problem.",
"   </p>",
"   <p>",
"    Despite these limitations, evidence that PPM is associated with residual pulmonary hypertension and increased mortality provides a rationale for implanting a mitral valve prosthesis with largest EOA for a given annulus size; the inability to completely avoid PPM provides further support for the strategy of repairing rather than replacing the valve, when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/4,43\">",
"     4,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Valve repair versus valve replacement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hospital volume and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a modest relationship between short-term outcome after mitral valve replacement and the volume of procedures performed at the hospital. This was illustrated in a review of the Medicare database, which found that the adjusted in-hospital and 30-day mortality was inversely related to volume, ranging from 11.6 percent in hospitals performing &gt;199 procedures per year to 15 percent in those performing &lt;43 per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Minimally invasive surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data on the use of minimally invasive mitral valve surgery in patients with chronic MR. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/38/30310?source=see_link\">",
"     \"Minimally invasive aortic and mitral valve surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CONCURRENT TRICUSPID REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant tricuspid regurgitation (TR) is common at the time of and following mitral valve surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Observational studies indicate that the presence of significant pre-operative TR is a predictor of increased post-operative mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/47\">",
"     47",
"    </a>",
"    ] and development of significant TR late post-operatively is also associated with increased mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/48\">",
"     48",
"    </a>",
"    ]. Tricuspid repair can prevent progression of TR and improve heart failure symptoms, although an impact on survival has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/45,47\">",
"     45,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determining the need for TR repair at the time of mitral (or aortic) valve surgery can be difficult since significant TR frequently develops after left-sided valve surgery in some patients with no or mild TR at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/45,46,48\">",
"     45,46,48",
"    </a>",
"    ]. Among patients with mitral valve disease, concurrent tricuspid regurgitation (TR) can be functional or, in patients with mitral valve prolapse, due to concurrent tricuspid valve prolapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/149?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of tricuspid regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequent development of significant TR following left-sided valve surgery is illustrated by the following reports :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of patients with MR due to a variety of causes (including mitral valve prolapse, ischemic and rheumatic disease), TR increased by more than two grades in 48 percent of patients who underwent mitral valve repair alone at a mean of five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/45\">",
"       45",
"      </a>",
"      ]. TR increased by more than two grades in only 2 percent of those who received mitral repair with concomitant tricuspid repair.",
"     </li>",
"     <li>",
"      In a study of patients who received mitral valve repair for functional ischemic MR, moderate to severe TR developed in 74 percent after 3 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of patients followed for a mean of 5 years after mitral or aortic valve surgery (45 percent with rheumatic valve disease), moderate or severe TR developed in 7 percent of those with no or trace TR and in 20 percent of those with mild TR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited evidence is available on predictors of late development of significant TR. Preoperative tricuspid annular dilatation has been used as a criterion for tricuspid repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/45,49\">",
"     45,49",
"    </a>",
"    ], although evidence for annular dilation as a risk factor for development of TR is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Risk factors for development of significant TR included female gender, rheumatic valve disease, atrial fibrillation, and peak TR gradient at follow-up in one analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the following recommendations for correcting TR at the time of mitral valve repair for severe MR from the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valve guidelines with 2008 focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concurrent tricuspid valve repair is indicated in patients with severe TR. A similar recommendation is included in the 2007 ESC guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concurrent tricuspid annuloplasty is indicated in patients with mitral valve prolapse who have significant tricuspid annular dilatation (annular diameter from the anteroseptal to anteroposterior commissure &ge;70 mm) or pulmonary hypertension even when there is only mild to moderate TR.",
"     </li>",
"     <li>",
"      Concurrent tricuspid annuloplasty is reasonable in patients undergoing mitral repair without mitral valve prolapse who have mild to moderate TR and tricuspid annular dilatation or pulmonary hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While significant tricuspid dilatation is defined as an annular major axis of &ge;70 mm (measured in the operating room) in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ], significant dilatation of the tricuspid annulus may be alternatively defined as an annular minor axis &gt;40 mm or &gt;21",
"    <span class=\"nowrap\">",
"     mm/m2",
"    </span>",
"    BSA measured in the four-chamber view as cited in the 2007 ESC guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/6,49\">",
"     6,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with chronic MR who undergo valve repair or replacement often have concomitant atrial fibrillation (AF). While valve surgery improves hemodynamic status, AF usually persists.",
"   </p>",
"   <p>",
"    Several intraoperative procedures have been developed to manage AF at the time of mitral valve surgery, either by preventing recurrence of the arrhythmia or by reducing the embolic risk. A number of studies have demonstrated the efficacy of performing a combined procedure that includes either a maze procedure or radiofrequency or cryoablation in addition to mitral valve surgery. Any of these procedures markedly reduces the frequency of persistent AF without a significant increase in operative complications. The data supporting these approaches are presented separately. The potential utility of mitral valve repair combined with surgical maze to treat patients with new onset AF with moderate MR has not been evaluated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=see_link&amp;anchor=H10#H10\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\", section on 'Concurrent mitral valve surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LEFT ATRIAL APPENDAGE OBLITERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amputation or ligation of the left atrial appendage during mitral valve surgery can be performed to remove a potential source of embolism. Although this approach was recommended by the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ], there are only limited data suggesting that the risk of stroke is reduced. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21686?source=see_link\">",
"     \"Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Choice of procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are consistent with the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2008 focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend mitral valve repair rather than mitral valve replacement if the anatomy is appropriate, including patients with rheumatic mitral valve disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/21\">",
"       21",
"      </a>",
"      ] and mitral valve prolapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/53/36697/abstract/22\">",
"       22",
"      </a>",
"      ]&nbsp;(",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The procedure should be performed at experienced surgical centers. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Valve repair versus valve replacement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Valve anatomy on echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require mitral valve replacement, the choice is between a mechanical valve, which requires life-long anticoagulation, and bioprosthetic valve, which does not require anticoagulation but has limited durability, primarily in patients under age 65. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Mechanical versus bioprosthetic valve'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=see_link&amp;anchor=H5#H5\">",
"       \"Complications of prosthetic heart valves\", section on 'Structural failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend a bioprosthetic valve in patients who cannot or will not take or have a clear contraindication to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest a mechanical valve in patients under age 65 who have long-standing AF, since anticoagulation is warranted for the AF (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest a bioprosthetic valve in patients &ge;65 years of age, since limited durability is much less of an issue in older patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients under age 65 who are in sinus rhythm, patient preference plays a central role in the choice of valve. The choice of a bioprosthetic valve should only be considered after a detailed discussion with the patient of the risks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy compared to the likelihood of repeat valve replacement in the future.",
"   </p>",
"   <p>",
"    In highly selected patients, other forms of surgical intervention, including left ventricular reconstruction and cardiac transplantation, may be considered. These issues as well as the management of ischemic and functional MR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35143?source=see_link\">",
"     \"Surgical management of heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Concurrent tricuspid valve surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with concurrent tricuspid regurgitation (TR) that might be corrected at the time of mitral valve surgery (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Concurrent tricuspid repair'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend tricuspid valve repair in patients with severe TR (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend concurrent tricuspid annuloplasty in patients with mitral valve prolapse who have significant tricuspid annular dilatation (annular diameter from the anteroseptal to anteroposterior commissure &ge;70 mm) or pulmonary hypertension even when there is only mild to moderate TR (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest concurrent tricuspid annuloplasty in patients undergoing mitral repair without mitral valve prolapse who have mild to moderate TR and tricuspid annular dilatation or pulmonary hypertension (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/1\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/2\">",
"      Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005; 352:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/3\">",
"      Ling LH, Enriquez-Sarano M, Seward JB, et al. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation 1997; 96:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/4\">",
"      Crawford FA Jr. Residual pulmonary artery hypertension after mitral valve replacement: size matters! J Am Coll Cardiol 2005; 45:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/5\">",
"      Lin SS, Lauer MS, Asher CR, et al. Prediction of coronary artery disease in patients undergoing operations for mitral valve degeneration. J Thorac Cardiovasc Surg 2001; 121:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/6\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/7\">",
"      Carabello BA. Is it ever too late to operate on the patient with valvular heart disease? J Am Coll Cardiol 2004; 44:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/8\">",
"      Suri RM, Schaff HV, Dearani JA, et al. Survival advantage and improved durability of mitral repair for leaflet prolapse subsets in the current era. Ann Thorac Surg 2006; 82:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/9\">",
"      Gillinov AM, Cosgrove DM, Blackstone EH, et al. Durability of mitral valve repair for degenerative disease. J Thorac Cardiovasc Surg 1998; 116:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/10\">",
"      Flameng W, Herijgers P, Bogaerts K. Recurrence of mitral valve regurgitation after mitral valve repair in degenerative valve disease. Circulation 2003; 107:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/11\">",
"      David TE, Ivanov J, Armstrong S, et al. A comparison of outcomes of mitral valve repair for degenerative disease with posterior, anterior, and bileaflet prolapse. J Thorac Cardiovasc Surg 2005; 130:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/12\">",
"      Saiki Y, Kasegawa H, Kawase M, et al. Intraoperative TEE during mitral valve repair: does it predict early and late postoperative mitral valve dysfunction? Ann Thorac Surg 1998; 66:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/13\">",
"      Eguchi K, Ohtaki E, Matsumura T, et al. Pre-operative atrial fibrillation as the key determinant of outcome of mitral valve repair for degenerative mitral regurgitation. Eur Heart J 2005; 26:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/14\">",
"      Lim E, Barlow CW, Hosseinpour AR, et al. Influence of atrial fibrillation on outcome following mitral valve repair. Circulation 2001; 104:I59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/15\">",
"      Feldman T, Cilingiroglu M. Percutaneous leaflet repair and annuloplasty for mitral regurgitation. J Am Coll Cardiol 2011; 57:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/16\">",
"      Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation 1999; 99:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/17\">",
"      Krayenbuehl HP. Surgery for mitral regurgitation. Repair versus valve replacement. Eur Heart J 1986; 7:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/18\">",
"      Enriquez-Sarano M, Schaff HV, Orszulak TA, et al. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis. Circulation 1995; 91:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/19\">",
"      Galloway AC, Colvin SB, Baumann FG, et al. Current concepts of mitral valve reconstruction for mitral insufficiency. Circulation 1988; 78:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/20\">",
"      Lee EM, Shapiro LM, Wells FC. Superiority of mitral valve repair in surgery for degenerative mitral regurgitation. Eur Heart J 1997; 18:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/21\">",
"      Yau TM, El-Ghoneimi YA, Armstrong S, et al. Mitral valve repair and replacement for rheumatic disease. J Thorac Cardiovasc Surg 2000; 119:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/22\">",
"      Mohty D, Orszulak TA, Schaff HV, et al. Very long-term survival and durability of mitral valve repair for mitral valve prolapse. Circulation 2001; 104:I1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/23\">",
"      Thourani VH, Weintraub WS, Guyton RA, et al. Outcomes and long-term survival for patients undergoing mitral valve repair versus replacement: effect of age and concomitant coronary artery bypass grafting. Circulation 2003; 108:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/24\">",
"      Moss RR, Humphries KH, Gao M, et al. Outcome of mitral valve repair or replacement: a comparison by propensity score analysis. Circulation 2003; 108 Suppl 1:II90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/25\">",
"      Enriquez-Sarano M, Schaff HV, Frye RL. Mitral regurgitation: what causes the leakage is fundamental to the outcome of valve repair. Circulation 2003; 108:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/26\">",
"      Enriquez-Sarano M, Freeman WK, Tribouilloy CM, et al. Functional anatomy of mitral regurgitation: accuracy and outcome implications of transesophageal echocardiography. J Am Coll Cardiol 1999; 34:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/27\">",
"      Hellemans IM, Pieper EG, Ravelli AC, et al. Prediction of surgical strategy in mitral valve regurgitation based on echocardiography. Interuniversity Cardiology Institute of The Netherlands. Am J Cardiol 1997; 79:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/28\">",
"      Hammermeister KE, Sethi GK, Henderson WG, et al. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. N Engl J Med 1993; 328:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/29\">",
"      Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/30\">",
"      Grunkemeier GL, Starr A, Rahimtoola SH. Prosthetic heart valve performance: long-term follow-up. Curr Probl Cardiol 1992; 17:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/31\">",
"      Ruel M, Chan V, B&eacute;dard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults &lt;60 years of age. Circulation 2007; 116:I294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/32\">",
"      Hansen DE, Cahill PD, DeCampli WM, et al. Valvular-ventricular interaction: importance of the mitral apparatus in canine left ventricular systolic performance. Circulation 1986; 73:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/33\">",
"      Sarris GE, Cahill PD, Hansen DE, et al. Restoration of left ventricular systolic performance after reattachment of the mitral chordae tendineae. The importance of valvular-ventricular interaction. J Thorac Cardiovasc Surg 1988; 95:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/34\">",
"      Rozich JD, Carabello BA, Usher BW, et al. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation 1992; 86:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/35\">",
"      Goldman ME, Mora F, Guarino T, et al. Mitral valvuloplasty is superior to valve replacement for preservation of left ventricular function: an intraoperative two-dimensional echocardiographic study. J Am Coll Cardiol 1987; 10:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/36\">",
"      Goldfine H, Aurigemma GP, Zile MR, Gaasch WH. Left ventricular length-force-shortening relations before and after surgical correction of chronic mitral regurgitation. J Am Coll Cardiol 1998; 31:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/37\">",
"      Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation: implications for management. Circulation 2008; 118:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/38\">",
"      Li M, Dumesnil JG, Mathieu P, Pibarot P. Impact of valve prosthesis-patient mismatch on pulmonary arterial pressure after mitral valve replacement. J Am Coll Cardiol 2005; 45:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/39\">",
"      Magne J, Mathieu P, Dumesnil JG, et al. Impact of prosthesis-patient mismatch on survival after mitral valve replacement. Circulation 2007; 115:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/40\">",
"      Lam BK, Chan V, Hendry P, et al. The impact of patient-prosthesis mismatch on late outcomes after mitral valve replacement. J Thorac Cardiovasc Surg 2007; 133:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/41\">",
"      Jamieson WR, Germann E, Ye J, et al. Effect of prosthesis-patient mismatch on long-term survival with mitral valve replacement: assessment to 15 years. Ann Thorac Surg 2009; 87:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/42\">",
"      Bolman RM 3rd. Survival after mitral valve replacement: does the valve type and/or size make a difference? Circulation 2007; 115:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/43\">",
"      Pibarot P, Dumesnil JG. Prosthesis-patient mismatch in the mitral position: old concept, new evidences. J Thorac Cardiovasc Surg 2007; 133:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/44\">",
"      Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/45\">",
"      Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg 2005; 79:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/46\">",
"      Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation 2005; 112:I453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/47\">",
"      Chan V, Burwash IG, Lam BK, et al. Clinical and echocardiographic impact of functional tricuspid regurgitation repair at the time of mitral valve replacement. Ann Thorac Surg 2009; 88:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/48\">",
"      Song H, Kim MJ, Chung CH, et al. Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery. Heart 2009; 95:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/53/36697/abstract/49\">",
"      Colombo T, Russo C, Ciliberto GR, et al. Tricuspid regurgitation secondary to mitral valve disease: tricuspid annulus function as guide to tricuspid valve repair. Cardiovasc Surg 2001; 9:369.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8138 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-201.65.114.212-30F76E55B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36697=[""].join("\n");
var outline_f35_53_36697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREOPERATIVE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Surgical risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predicting coronary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VALVE REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Valve repair outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Recurrent MR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Percutaneous repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VALVE REPAIR VERSUS VALVE REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Comparison of outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Reoperation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cause of MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Valve anatomy on echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      VALVE REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mechanical versus bioprosthetic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chordal preservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prosthetic valve-patient mismatch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hospital volume and outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Minimally invasive surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CONCURRENT TRICUSPID REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LEFT ATRIAL APPENDAGE OBLITERATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Choice of procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Concurrent tricuspid valve surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8138|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/56/41869\" title=\"figure 1\">",
"      NYHA repair vs replacement MV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/22/5476\" title=\"figure 2\">",
"      Mitral valve structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8138|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/19/35132\" title=\"table 1\">",
"      Valve surgery nonischemic MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/61/29659\" title=\"table 2\">",
"      ACC AHA selection mitral valve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/5/7252?source=related_link\">",
"      Estimating the mortality risk of valvular surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/149?source=related_link\">",
"      Etiology, clinical features, and evaluation of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25096?source=related_link\">",
"      Indications for corrective surgery in severe chronic primary mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/38/30310?source=related_link\">",
"      Minimally invasive aortic and mitral valve surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6649?source=related_link\">",
"      Natural history of chronic mitral regurgitation in mitral valve prolapse and flail mitral leaflet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21686?source=related_link\">",
"      Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35143?source=related_link\">",
"      Surgical management of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42040?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of mitral valve disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34377?source=related_link\">",
"      Valvular heart disease in elderly adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_53_36698="Nodular lymphoid hyperplasia Low";
var content_f35_53_36698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55114%7EPULM%2F68369%7EPULM%2F82569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55114%7EPULM%2F68369%7EPULM%2F82569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular lymphoid hyperplasia in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows extensive polyclonal lymphoid infiltration of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular lymphoid hyperplasia in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows heterogenous foci of lymphocytes and plasma cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular lymphoid hyperplasia in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows a focus of small lymphocytes, which proved polyclonal by immunostaining.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36698=[""].join("\n");
var outline_f35_53_36698=null;
var title_f35_53_36699="Using MDI PI";
var content_f35_53_36699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Technique for use of a metered dose inhaler (MDI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Shake canister vigorously for 5 seconds.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uncap mouthpiece and check for loose objects in the device.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Insert MDI into spacer. Hold the MDI upright with the index finger on the top of the medication canister and the thumb supporting the bottom of the inhaler. You may need to use the other hand to hold the spacer.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Breathe out normally.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Close lips around spacer. For spacers that have a mask, hold the mask snugly to the face. If no spacer is available, close lips around mouthpiece or position it about 4 cm from the mouth.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Keep tongue away from the spacer opening or mouthpiece.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Press down the top of the medication canister with the index finger to release the medication.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       At the same time as the canister is pressed, inhale deeply and slowly through the mouth until the lungs are completely filled; this should take 4 to 6 seconds.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hold the medication in the lungs as long as possible (4 to 10 seconds) before exhaling. If using a spacer, you may inhale a second time and hold the breath if needed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If a second puff is needed, wait approximately 15 to 30 seconds between puffs, or long enough to perform the next inhalation properly. Shake canister again before use.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recap mouthpiece.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rinse your mouth with water after using an inhaled glucocorticoid, and spit the water out rather than swallowing it.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These instructions do NOT apply to dry powder inhalers. Cleaning instructions are provided separately.",
"    <div class=\"footnotes\">",
"     More detailed information about individual medication formulations can be found at file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36699=[""].join("\n");
var outline_f35_53_36699=null;
var title_f35_53_36700="Algorithm genet couns refer BRCA";
var content_f35_53_36700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Algorithm for genetic counseling referral from the Clinical Cancer Genetics Program at Ohio State University",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-Jewish families",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        High risk* breast-ovarian; any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One case of breast cancer &le;40-years-old in a first or second-degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One first or second-degree relative with both breast and ovarian cancer at any age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Two cases of breast cancer in first or second-degree relatives if one is diagnosed at &le;50 years of age or is bilateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One first or second-degree relative with breast cancer diagnosed at &le;50-years-old or bilateral",
"        <strong>",
"         and",
"        </strong>",
"        one first or second-degree relative with ovarian cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Three cases of breast and ovarian cancer (at least one case of ovarian cancer) in first or second-degree relatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Two cases of ovarian cancer in first or second-degree relatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One case of male breast cancer in a first or second-degree relative if another first or second degree relative has (male or female) breast or ovarian cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Moderate risk* breast; any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Two first-degree relatives if both diagnosed between 51 and 60 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One first degree and one second-degree relative (mother or sister and maternal aunt or maternal grandmother), if the sum of their ages is &le;118-years-old",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Moderate risk ovarian:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One first-degree relative with ovarian cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Jewish families",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        High risk* breast-ovarian; any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One case of breast cancer &le;50-years-old in a first or second-degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One case of ovarian cancer at any age in a first or second-degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A first or second degree relative with breast cancer at any age if another first or second degree relative has breast and/or ovarian cancer at any age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One case of male breast cancer in a first or second-degree relative",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * High risk: Family histories suggestive of a hereditary cancer susceptibility syndrome where the individual would benefit from referral to a cancer genetics professional and increased cancer surveillance; Moderate risk: Family histories not diagnostic of a hereditary cancer susceptibility syndrome but conferring an increased risk for cancer, requiring increased cancer surveillance.",
"    </div>",
"    <div class=\"reference\">",
"     Hampel H, et al. J Med Genet 2004; 41:81.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36700=[""].join("\n");
var outline_f35_53_36700=null;
var title_f35_53_36701="Right atrial pressure tracing";
var content_f35_53_36701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right atrial pressure tracing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schematic diagram shows the different components of the right atrial pressure tracing. A simultaneous ECG is shown to demonstrate the timing of the different components.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Gore, JM, Alper, JS, Benotti, JR, et al. Handbook of hemodynamic monitoring, 1st ed, Boston, Little Brown &amp; Co, 1985.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36701=[""].join("\n");
var outline_f35_53_36701=null;
var title_f35_53_36702="Mayo dissecting scissors";
var content_f35_53_36702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mayo dissecting scissors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 176px; height: 457px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blunt-sharp version.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36702=[""].join("\n");
var outline_f35_53_36702=null;
var title_f35_53_36703="Tetralogy Fallot LV angiogram";
var content_f35_53_36703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular angiogram in tetralogy of Fallot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The angiogram of the left ventricle (LV) in a patient with tetralogy of Fallot was obtained with the camera in a long axial oblique projection. There is a large malaligned ventricular septal defect (*) with the aorta (AO) overriding the intraventricular septum (IVS).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_53_36703=[""].join("\n");
var outline_f35_53_36703=null;
